Faculty & Staff Scholarship
2019

MicroRNAs and the Genetic Nexus of Brain Aging,
Neuroinflammation, Neurodegeneration, and Brain Trauma
Saumyendra N. Sarkar
West Virginia University

Ashley E. Russell
West Virginia University

Russell Elizabeth B. Engler-Chiurazzi
West Virginia University

Keyana N. Porter
West Virginia University

James W. Simpkins
West Virginia University, jwsimpkins@hsc.wvu.edu

Follow this and additional works at: https://researchrepository.wvu.edu/faculty_publications
Part of the Neurosciences Commons

Digital Commons Citation
Sarkar, Saumyendra N.; Russell, Ashley E.; Engler-Chiurazzi, Russell Elizabeth B.; Porter, Keyana N.; and
Simpkins, James W., "MicroRNAs and the Genetic Nexus of Brain Aging, Neuroinflammation,
Neurodegeneration, and Brain Trauma" (2019). Faculty & Staff Scholarship. 2189.
https://researchrepository.wvu.edu/faculty_publications/2189

This Article is brought to you for free and open access by The Research Repository @ WVU. It has been accepted
for inclusion in Faculty & Staff Scholarship by an authorized administrator of The Research Repository @ WVU. For
more information, please contact ian.harmon@mail.wvu.edu.

Volume 10, Number 2; 329-352, April 2019
http://dx.doi.org/10.14336/AD.2018.0409

Review

MicroRNAs and the Genetic Nexus of Brain Aging,
Neuroinflammation, Neurodegeneration, and Brain
Trauma
Saumyendra N. Sarkar, Ashley E. Russell, Elizabeth B. Engler-Chiurazzi, Keyana N. Porter, and
James W. Simpkins*
Center for Basic and Translational Stroke Research, Rockefeller Neuroscience Institute, West Virginia
University, Morgantown, WV 26506, USA
[Received February 10, 2018; Revised April 6, 2018; Accepted April 9, 2018]

ABSTRACT: Aging is a complex and integrated gradual deterioration of cellular activities in specific organs of
the body, which is associated with increased mortality. This deterioration is the primary risk factor for major
human pathologies, including cancer, diabetes, cardiovascular disorders, neurovascular disorders, and
neurodegenerative diseases. There are nine tentative hallmarks of aging. In addition, several of these hallmarks
are increasingly being associated with acute brain injury conditions. In this review, we consider the genes and
their functional pathways involved in brain aging as a means of developing new strategies for therapies targeted
to the neuropathological processes themselves, but also as targets for many age-related brain diseases. A single
microRNA (miR), which is a short, non-coding RNA species, has the potential for targeting many genes
simultaneously and, like practically all other cellular processes, genes associated with many features of brain
aging and injury are regulated by miRs. We highlight how certain miRs can mediate deregulation of genes
involved in neuroinflammation, acute neuronal injury and chronic neurodegenerative diseases. Finally, we review
the recent progress in the development of effective strategies to block specific miR functions and discuss future
approaches with the prediction that anti-miR drugs may soon be used in the clinic.
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Aging is a complex and integrated gradual deterioration
of cellular activities in organs of the body that corresponds
with increased morbidity and mortality [1]. Various
tissues experience progressive, functional decreases over
time, which manifest as age-related phenotypes and
diseases, including cancer, diabetes, cardiovascular
disorders, neurovascular disorders, and neurodegenerative diseases [2-6]. This review outlines some of
the important hallmarks of aging, together with examples
of specific miRs that are known to be involved in each
specifically, as well as aging in general (Fig. 1). There are
nine tentative “hallmarks” of aging, as recently described
by Lopez-Otin et al. [1]. These hallmarks include (i)

gradual deterioration in repairing damaged DNA, (ii)
altered nutrient signaling, (iii) loss of protein homeostasis,
(iv) mitochondrial dysfunction, (v) stem cell exhaustion,
(vi) telomere shortening, (vii) dysregulation of the genes
by epigenetic and mRNA processing changes, (viii)
premature cellular senescence, and (ix) altered intracellular communication.
The implications for heterochronic (young-old)
parabiosis experimental findings in mice are profound;
circulating factors can inhibit the aging phenotype by
influencing the resident tissues, which have the inherent
potential to regenerate and function analogous to juvenile
tissues [7-10]. Systemic administration of plasma derived
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from juvenile to aged mice reverses many aging
phenotypes including cardiac hypertrophy [8], synaptic
plasticity dysfunction and cognitive deficits [10], muscle
degeneration [9], and hypo-perfusion of the brain [7].
GDF11, a member of the transforming growth factor beta
(TGF-β) superfamily, is a circulating factor that declines
with age, and may be responsible for some of these
effects, as it has been shown to reduce age-related cardiac
hypertrophy [9]. Further, exposing young mice to plasma
from old mice decreases synaptic plasticity, and impairs
contextual fear conditioning, spatial learning, and
memory [11]. A candidate circulating factor in aged
murine plasma is C-C Motif Chemokine Ligand 11,
(CCL11), a chemokine gene family member. It has been
reported that the levels of CCL11 are increased in the
plasma and cerebrospinal fluid of healthy aging humans
[11]. Thus, the systemic immune related factor, CCL11,
is a potentially critical contributor to the susceptibility of
the aging brain to cognitive impairments.
The factors regulating the expression of GDF11 and
CCL11, the tissues involved in their production, their
mechanism(s) of action, and why their expression changes
during aging remains yet to be determined. Besides
proteins, other molecules, such as RNA and exosomes
containing miRs can induce or inhibit the aging
phenotypes [12]. Molecular components that govern both
the structure and function of vital organs in the body are
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encoded in the genome and regulated by the expression of
various genes. As a consequence, changes in regulation of
gene expression during aging might be directly related to
the expression of the aging phenotype, and age-related
pathology in a specific organ. Transcriptional profiling of
single cells, including neurons, microglia, astrocytes,
oligodendrocytes, and endothelial cells, by specific RNA
sequencing analysis of human prefrontal cortex of
subjects ranging in age from 26 to 106 years, defines two
sets of aging-related changes in gene expression [13, 14].
First, one set show reduced expression, while a
second set of genes show increased expression, after age
40. According to Gene Ontology (GO) and Kyoto
Encyclopedia of Genes and Genomes (KEGG) enriched
score categories, the first sets of genes (reduced
expression) play a central role in grey and white matter
plasticity, mitochondrial function, learning and memory,
intracellular transport, oxidative and cellular stress
resistance, DNA repair enzymes, epigenetic and
transcription processes. The second set of genes
(increased
expression)
is
categorized
as
neuroinflammation (inflammaging) genes. GO and
KREGG analyses of expression profiles of miRs in the
aging cerebellum and cortex of both chimpanzees and
human have suggested that upregulated miR target genes
are factors in cognitive decline and neurodegenerative
disorders during aging [15].

Figure 1. The hallmarks of mammalian aging and the miRs that target genetic networks involving these pathways.
Associated miRs with each of the hallmark of aging are indicated. The miRs involving more than one aspect of aging are bolded.
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Figure 2. miR Biogenesis and Post-transcriptional Gene Regulation.

One of the main reasons for changes in gene expression
during aging is epigenetic regulation. This includes
alterations in the methylated states of regulatory DNA
sequences, covalent modifications of histone proteins, and
the expression of regulatory non-coding RNAs, such as
miRs. Presently, thousands of miRs have been identified
in plants and mammals, and as of today, over 1881 human
miRs
have
been
reported
in
miRBase
[http://www.mirbase.org/; 16]. It is important to note that
miRBase miRNAs are only sequence based, and many of
them are yet to be functionally validated. As such, the
aforementioned number of putative human miRNAs is
likely an over estimate. miRs have recently emerged as
important regulators of cellular senescence and aging.
Several reviews describing miRs and their role in the
aging process have been published [17, 18].
The cellular and molecular hallmarks of aging have
been categorized [1], and the present review assesses
many of the candidate hallmarks of aging, together with
examples of specific miRs that are known to be involved
in aging. Here we highlight how certain miRs can mediate
dysregulation of genes involved in aging, which are also
linked with aging-related diseases of the brain. Further,
we describe the role of miRs in the brain’s inflammatory
response during aging and age-related diseases. Finally,
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we consider the role of miRs in acute brain damage from
stroke, as well as neurodegenerative diseases.
miRs: Genomics, Biogenesis, and Function
miRs are small, endogenous ∼22 nucleotide RNAs whose
biogenesis occurs in all mammalian and plant cells and
can play important regulatory roles by targeting mRNAs
for cleavage or translational repression. Many miR genes
are clustered in the same region of a chromosome, and
some miRs have homologues; e.g. miR-34 is a family of
three (miR-34a, -34b, and -34c); the reader is referred to
the GeneCards website (http://www.genecards .org).
miR genes are transcribed by RNA pol II or pol III as
long precursors (pri-miRs) that are then cleaved into
smaller RNAs (pre-miRs) by the microprocessor in the
nucleus. Pre-miRs are then exported by exportin 5 into the
cytoplasm, where the enzyme Dicer cleaves them to
produce short double stranded RNA molecules. Of the
two strands, one is generally referred to as the primary, or
mature miR sequence, while the other is known as the
passenger strand (denoted as miR*) [19]. The mature miR
sequence is eventually loaded into the RNA Induced
Silencing Complex (RISC) and guides the complex in
mRNA target binding by base pairing. The passenger
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strand is usually degraded, however some evidence
suggests that it can also interact with RISC and exert
regulatory roles [19]. By pairing with target mRNAs,
miRs are able to downregulate gene expression by
targeting mRNA for degradation or transcriptional
repression (Fig. 2).
Defective Damaged DNA Repair Pathways
Cells continuously encounter various DNA-damaging
factors, which give rise to DNA damage throughout life.
Cells remove endogenous and exogenous sources of DNA
damage through their conserved DNA repair and cell
cycle checkpoint pathways, which help cells to either
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maintain genomic stability, or prevent cells from entering
mitosis [20]. Multiple DNA repair pathways have evolved
to resolve various DNA lesions. These pathways include
base excision repair (BER)/single strand break repair
(SSBR), homologous recombination repair (HR), nonhomologous end-joining repair (NHEJ), nucleotide
mismatch repair (NMR), translesion DNA synthesis
(TLS), and telomere repair [21]. Several studies have
shown that expression of DNA repair enzymes decreases
during aging. One possible mechanism by which this
reduction of enzymes occurs could be that aging induces
miR expression, which targets repair genes, and represses
their translation.

Figure 3. MicroRNAs Target Enzyme-Scaffold Complex. Chains of molecules along with XRCC1
scaffolding protein recognize ROS induced DNA damage and recruit six enzymes to form the BER/SSBRscaffold complex. MicroRNAs shown are identified by in silico analysis and target many components of this
complex.

There are many excellent reviews published on the
role of miRs and exogenous DNA damage responses in
proliferating cells, but the role of miRs and exogenous
DNA damage in terminally differentiated cells has not
been extensively reviewed. Defective repair of oxidized
DNA has been noted in the brains of patients with
Alzheimer’s disease (AD), and elevated levels of oxidized
DNA bases were observed in the cerebrospinal fluid of
AD patients. The DNA repair mechanism BER/SSBR is
the predominant mechanism for the removal of oxidized
DNA bases and oxidized DNA break termini, which are
formed at high frequency in neuronal cells of the adult
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brain. BER/SSBR proceeds through five steps, involving
six enzymes, including poly-(ADP ribose) polymerase
(PARP1), uracil DNA glycosylase (UDG), Apurinic/
apyrimidine endonuclease (APE1), DNA polymerase beta
(POLB), DNA ligase1 (LIG1), flap structure-specific
endonuclease (FEN1) and the scaffold protein, XRCC1,
which plays a key role in coordinating BER/SSBR
complex formation (Fig. 3). In humans, a function
mutation in XRCC1 results in a phenotype that is
characterized by neurodegeneration in the cerebellum and
basal ganglia [22]. Moreover, neural specific loss of
XRCC1 in mice leads to abnormal hippocampal function
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[23]. Experimental evidence linking targets of various
miRs that are induced during aging with BER/SSBR is
scant. In silico analysis (Sarkar, unpublished observation)
revealed that miR-34a, whose expression is known to be
increased in the aging heart and brain, targets XRCC1,
FEN1, and UDG. Additional miRs target BER/SSBRassociated enzymes and proteins: miR-181 targets
PARP1; miR-146b targets XRCC1 (Fig. 3).
miRs and Deregulated Nutrient Sensing
Deregulated nutrient sensing is a hallmark of aging. The
intracellular signaling pathway of insulin-like growth
factor (IGF-1)/insulin and downstream intracellular
effectors such as AKT, mTOR, and FOXO are the most
conserved aging-controlling pathways in evolution [24].
Age-specific profiling of miRs in skeletal muscle
identified miR-126 as a regulator of muscle plasticity, and
an inhibitor of IGF-1 signaling [25]. Other published work
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has shown that upregulation of miR-190b plays a role in
decreasing IGF-1, leading to the induction of insulin
resistance [26]. Another miR, miR-1, targets the IGF-1
signal transduction pathways in both cardiac and skeletal
muscles [27]. Several other studies have also reported that
multiple miRs regulate the components of nutrient
sensing pathways, such as miR-1, miR-320, and miR-206
by targeting IGF-1 [28] and miR-216a, miR-217, and
miR-21 by targeting phosphatase and tensin homolog
(PTEN) [29]. Further, there are reports showing that
several miRs regulate the expression of SIRT1, an
ortholog of Sir2, which is implicated in the regulation of
life span, stress resistance, and metabolism [30].
Additionally, the expression of miR-217 increases during
aging and targets SIRT1 in endothelial cells [31]. miR34a, has also been found to target SIRT1 [32], implying
that there might be a connection between miR-34a and
aging signaling pathways, as shown in Fig. 4.

Figure 4. miRs involved in deregulation of nutrient sensing pathway. Schematic diagram showing
the growth hormone (GH) and insulin growth factor 1 (IGF-1) signaling pathway and its association with
dietary restriction and aging. GH = Growth Hormone, PTEN = Phosphatase and Tensin homolog, PI3K
= Phosphatidylinositol-4,5-bisphosphate 3-kinase, AKT = Protein kinase B, AMPK = AMP-activated
protein kinase, Sirt1 = sirtuin (silent mating type information regulation 2 homolog) 1, mTOR =
mechanistic target of rapamycin, PGC-1α = Peroxisome proliferator-activated receptor gamma
coactivator 1-alpha, FOXO = FOXO family of Forkhead transcription factors.

Aging and Disease • Volume 10, Number 2, April 2019

333

Sarkar SN., et al

miR Deregulates Proteostatis
Proteostasis involves mechanisms for the stabilization of
correctly folded proteins, as well as mechanisms for the
degradation of misfolded proteins by proteasomes and
lysosomes [33]. Impairment of proteostasis occurs in
aging and in age-related diseases [34]. Chronic expression
of unfolded, misfolded, or aggregated proteins is seen in
age-related pathologies, including AD and Parkinson’s
disease [35]. The genes, which are collectively called the
molecular chaperones network, have a central role in
proteostasis, as they are essential to preventing the
accumulation of misfolded proteotoxic states, which
commonly occurs in many neurodegenerative disorders
[36]. Major players in the chaperone network include
genes that encode heat shock proteins (HSP), HSP40,
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HSP20, HSP1OO, HSP110, HSP90, HSP72, and others
[37]. As with many other cellular processes, miRs are also
known to regulate the molecular chaperone network. The
expression of miR-320 increases during cardiac injury,
and has been shown to target HSP20 chaperone
molecules, which is a cardioactive protein [38]. Increased
expression of miR-106a, miR-26b, and miR-301b
deregulates HSP70-mediated autophagy, and alphasynuclein pathology in Parkinson’s disease [39]. In the
aging heart [40] and in AD patients’ brain [41], increased
expression of miR-34a and miR-146a has been reported.
In silico analysis (Sarkar unpublished observation)
identified HSP20, HSP40, HSP72 as targets of miR-34a
and HSP90 as a target for miR-146a (Fig. 5).

Figure 5. miRs specifically deregulate molecular chaperone specific pathway of proteostatis Oxidative
and ER stress induced unfolded proteins either refolded back by HSP chaperone or degraded by HSC chaperone
mediated ubiquitin-proteosome or lysomal pathways (Autophagy). Oxidative stress damages DNA and proteins
leading to their reduced function. A miR-induced decrease in repair mechanisms would then encourage aging.

miRNAs and Autophagy
HSPs are not the only regulators of proteostasis;
autophagy is another clearance system by which abnormal
intracellular proteins are degraded. Recent studies have
shown that miRNAs are involved in the induction of
autophagy, as well as the formation of mature
autophagosomes [42]. Autophagy consists of several
sequential steps, and various miRs target many of the
genes involved in these processes. First, autophagy
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induction is initiated by activation of the Unc-51 like
autophagy activating kinase (ULK) complex, which is
composed of ULK1/2, FIP200, ATG101 and ATG13 [43,
44]. It has been shown that miR-20a and miR-106b can
directly target ULK1 and suppress its expression [45],
while inhibition of miR-25 leads to autophagic cell death
by directly increasing ULK1 expression [46].
Additionally, a recent study has reported that ULK2, an
autophagy initiator, is a direct target of miR-885-3p [47].
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miRNA-30a/b, miRNA-376b, miR-216a, and miR17-5p inhibit Beclin-1 expression, which in turn
suppresses
initial
stages
of
vesicle
nucleation/autophagosome formation [48-51]. Beclin-1
can also be targeted by miR-519a, while miR-630 and
miR-374a can inhibit UVRAG, which interacts with
Beclin-1, leading to activation of autophagy [52].
Furthermore, it has been shown that miR-195 targets
ATG14, a critical component of the class III PI3K/Beclin1 complex for the nucleation of the autophagosomal
membrane [53]. Vesicle nucleation/ autophagosome
formation by RAB5A, a small GTPase, can induce
autophagosome formation by its interaction with hVPS34
(a lipid kinase) and Beclin-1. miRNA-101 targets RAB5A
to inhibit autophagy, implying that miR-101 modulates
autophagy at the step of vesicle nucleation [54, 55].
Various miRNAs are also involved in the late stage
process involving the retrieval and fusion by targeting the
ATG2, ATG9, UVRAG and ATG18 genes [56-58].
1.
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gradually declines. The high mobility group A2
(HMGA2) gene regulates stem cell pluripotency. Let-7
targets HMGA2 and increases p16 and p19 gene
expression, thereby controlling stem cell aging [63].
Another miR, miR-145, can inhibit human embryonic
stem cell differentiation by suppressing pluripotency
genes, such as Oct4, Sox2, and KIf4 [64]. Many
differentially expressed miRs, including let-7, miR-499,
mir-371, and miR-369 in mesenchymal stem cells induce
replicative senescence, which results in the loss of
stemness [65]. miR-34a, b, and c suppress somatic cell
reprogramming by repressing expression of the
pluripotency genes Nanog, Sox2, and N-myc [66]. miR720 also promotes differentiation by repressing the
expression of the Nanog gene [67]. As such, loss of
stemness during aging could arise due to the repression of
pluripotency genes by miRs.
miRs Involved in Telomere Shortening, Cellular
Senescence and Cardiac Aging

miRs Involved in Mitochondrial Dysfunction
Mitochondrial dysfunction is a feature of the aging brain
and heart. Due to their high energy demand, these two
organs are especially sensitive and vulnerable to any
abnormality in mitochondrial function. Transcriptional
profiling from individuals ranging from 26 to 106 years of
age defines a set of genes important for mitochondrial
function with severely reduced expression after age 40
[59]. These genes include ATP synthase, mitochondrial
F1α, and nuclear encoded cytochrome c synthase, all of
which are components of the electron transport chain.
Dysfunction of the mitochondrial electron transport chain
has also been associated with the pathophysiology of lateonset AD [60]. The most consistent defect in
mitochondrial electron transport enzymes in AD is a
deficiency in cytochrome c oxidase [61], which leads to
an increase in ROS production, a reduction in energy
stores, and a disturbance in energy metabolism [61].
Increased expression of various miRs in AD has
previously been reported [62]. Two miRs, miR-34a and
miR-146a, are of special interest because they target many
of the electron transport chain genes. Severe reductions of
electron transport chain proteins were observed in AD
brains from human patients [41]. We also observed a
severe
reduction
in
mitochondrial
oxidative
phosphorylation and key electron transport proteins when
miR-34a is over expressed in rat primary neurons [41].
miRs and Stem Cells Exhaustion
Genes that regulate stem cell properties, so called
“stemness genes”, control cell renewal, proliferation, and
quiescence, and during aging, the function of these genes
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Aging in humans and mice is accompanied by progressive
shortening of telomeres [68]. Telomere length is
controlled in cells; shorter telomeres are associated with
senescence, which can cause dysfunction in organs, while
longer telomeres are associated with diseases such as
cancer. Telomeres are maintained by the activity of a
complex
comprising
of
Telomerase
Reverse
Transcriptase (TERT), Telomerase RNA, Telomere
Repeat binding Factor1&2 (TERF1,2), and Dyskerin
Pseudouridine Synthase 1 [69]. Several miRs have been
linked with changes in telomere length: miR-138 targets
TERT transcript in a thyroid cancer cells [70]; miR-155
targets TERF1 [71]. It has also been shown that
overexpression of miR-34a in gall bladder cancer tissues
is associated with telomere shortening [72], and has been
shown to be involved in apoptosis and senescence [73].
Recently, Boon et al., [40] demonstrated that miR-34a
expression in human and mouse hearts increases in an
age-dependent manner. Increased miR-34a expression in
the aging mouse heart induces telomere attrition, causing
cardiomyocyte cell death and inhibition of myocardial
function. The authors identified a gene, PNUTS
(synonym, protein phosphatase 1 regulatory subunit 10
(PPP1R10)), as a novel target of miR-34a, which is known
to interact with TREF2 (Sarkar, unpublished data).
Further, in vivo antagomiR-34a-mediated inhibition
increases cardiac PNUTS levels, reduces cell death and
fibrosis following acute myocardial infarction, and
improves recovery of myocardial function [40]. In silico
analysis (Sarkar, unpublished) revealed that miR-34a also
targets TRET, and TREF2 genes. This downregulation
may cause telomere shortening in the aging heart, which
is currently associated with cellular senescence in
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cardiovascular cells, including cardiomyocytes, vascular
endothelial cells, and vascular smooth muscle cells,
resulting in cardiovascular diseases.
miRs and Changes in Control Over Gene Expression
Molecular components that govern the structure and
function of vital organs in the human body are encoded in
the genome and regulated by the expression of various
genes. As a consequence, changes in regulation of gene
expression levels during aging might be directly related to
the expression of the aging phenotype, and age-related
pathology within a specific organ. GO and KREGG
analyses of expression profiles of miRs in the aging
cerebellum and cortex of chimpanzees and humans has
shown that upregulated miR target genes are associated
with cognitive decline and neurodegenerative disorders
during aging [74]. There are various reasons for the
changes in gene expression by miRs during aging, which
includes alterations in the methylated states of regulatory
DNA sequences, covalent modifications of histone
proteins, changes in components of transcription
machinery protein complex, and import/export defects in
the nucleus.
miRs and DNA methylation
Notably, miRs can cause aberrant DNA methylation. For
example, the miR-29 gene family targets DNA methyl
transferases, DNMT3A and DNMT3B, in cancer cells
[75]. A conditional knockout of DNMT1 and DNMT3A
in forebrain excitatory neurons of mice causes abnormal
long-term synaptic plasticity in the hippocampal CA1
region, together with deficits in learning and memory
[76]. In silico analysis revealed that miR-146a also targets
DNMT3A (Sarkar, unpublished). miR-146a expression is
increased in human late-onset AD brains compared to
age-match controls [41].
miRs and Histone Modification
Alterations in histone acetylation in animal models have
been implicated in learning and memory, as well as
synaptic plasticity. Studies based on pharmacological
histone deacetylase (HDAC) inhibitors have primarily
focused on class I HDAC family members (HDAC1,
HDAC2, HDAC3, and HDAC8), with recent data
suggesting that brain deletion of Hdac2 facilitates
memory formation and synaptic plasticity [77]. However,
the role of class IIa HDACs (HDAC4, HDAC5, HDAC7,
and HDAC9) [77], which act as transcriptional repressors
and shuttle between the nucleus and cytoplasm in
response to intracellular signaling, is not well known [78].
Recently it has been shown that selective loss of Hdac4 in
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the brain results in impairments in both hippocampaldependent learning and memory, and long-term synaptic
plasticity. In silico analysis indicates that miR-34a and
miR-146a both target HDAC2 (Sarkar unpublished). As
described earlier, expression of both miRs are increased
in AD brain [41].
miRs and Changes in Components of Transcription
Machinery Protein Complex
One of the most crucial members of the transcription
machinery protein complex is Topoisomerase II (TOP2).
TOP2 removes torsional stress from chromosomal DNA
and facilitates gene transcription by introducing transient
DNA double-strand breaks (DSBs). Such DSBs are
immediately rejoined by TDP2 gene encoding tyrosyl
DNA phosphodiesterase-2, an enzyme that repairs TOP2induced DSBs. It has been shown that neuronal activity
triggers the formation of DNA double strand breaks in the
promoters of many of the early response genes that are
important for structural and functional synaptic plasticity
and memory [79]. In silico analysis indicates that miR34a directly targets both TOP2 and TDP2, as well as many
immediate early genes, including the gene NPAS4
(Sarkar, unpublished). The NPAS4 gene is crucial for
synaptic connections in excitatory and inhibitory neurons,
neural circuit plasticity, and memory formation [80].
Besides immediate early genes, many other genes
involved in synaptic plasticity and memory, whose
expressions in human prefrontal cortex declines during
aging, are also targets of miR-34a. Many synaptic
plasticity genes show reduced protein expression
associated with increased miR-34a expression [41]. In
silico analysis also indicates that miR-34a targets the
white matter plasticity gene, myelin regulatory factor
(Myrf), which is a transcription factor, and the master
regulator for myelination within the central nervous
system (Sarkar, unpublished). Deletion of Myrf prevents
mice from mastering complex motor learning tasks [81].
Thus, miR-34a targets many genes important for both
grey and white matter plasticity and could therefore
possibly impair cognitive function of the brain.
miRs and Inflammation
Inflammation is an evolutionary adaptation designed to
protect organisms from pathogenic infections. Resident
tissue innate immune cells have pattern recognition
receptors (PRRs) and are able to detect pathogen
associated molecular patterns (PAMPs) expressed on
microorganisms such as bacteria, and damage associated
molecular patterns (DAMPs), which are altered or
damaged endogenous ligands, usually released by
necrotic, senescent, and/or damaged cells. Among PRRs,
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toll-like receptors (TLRs) play a central role, since their
engagement activates a potent pro-inflammatory pathway,
which is involved in signaling by NF-kB, mitogen
activated protein kinases (MAPKs), and members of the
interferon regulatory factors [82].
In addition to fighting off infections, inflammatory
responses are generated to remove and restore damaged
tissue after injury. For example, intrahippocampal
injection of lipopolysaccharide (LPS) in amyloid
precursor protein (APP) transgenic mice triggers an
inflammatory response, resulting in transient clearance of
diffuse amyloid-β (Aβ) deposits [83, 84]. Unfortunately,
inflammation also has the capacity to damage healthy
surrounding tissue as well [85]. Many believe that in AD,
neuroinflammation is a driving force behind
neurodegeneration [86, 87]. Cytokines expressed by
activated glial cells or neurons may alter protein kinase
pathways and tau phosphorylation patterns within the
brain [88, 89]. The generation of reactive oxygen species
(ROS) [90] and nitric oxide (NO) [91] may also lead to
neuronal damage and subsequent death.
The body must be able to regulate and balance the
immune response to allow for the clearance of pathogens
and damaged tissue, while restricting the death of healthy
cells. A mounting body of evidence documents a group of
miRs that are involved in regulating inflammation. In
normal physiological conditions, transcription of miR165, miR-21 and miR-146a remains at low levels.
However, initiation of TLR signaling results in strong coinduction and subsequent upregulation of these miRs,
through pathways involving NF-κB signaling. It has been
shown that depending upon both their target genes and
affected tissue, miRs could play a dual function by
inhibiting, as well as inducing, inflammation by TLR
signals [92].
The Blood-Brain Barrier Prevents Infiltration from the
Periphery
The ways in which the CNS and the peripheral immune
system influence one another has been heavily studied
over the past few decades. As accumulating evidence
supports intricate immune-nervous system interactions
[93], we are beginning to understand how these two
complex systems interact.
Unlike the vasculature in the periphery, the
endothelial cells which comprise the BBB, form and
maintain tight junctions in response to factors secreted by
glial cells [94, 95]. In recent years, there has been a great
deal of research focusing on the functional role of the
BBB. Conclusive evidence shows that while tight
junctions are selectively permeable and provide
somewhat of a physical barrier, the BBB does not serve as
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an impenetrable blockade from all peripherally circulating
factors.
Clinical and epidemiological evidence suggests that
peripheral infection and systemic immune activation can
lead to cognitive impairments in adults [96-98]. Work
from animal models also suggests that systemic
inflammation leads to increased hippocampal
inflammation, behavioral deficits [99, 100], and AD-like
pathology, such as tau hyperphosphorylation, increased
Aβ42 accumulation and plaque formation, and learning
and memory impairments [101-104].
During normal physiological conditions, tight
junctions between endothelial cells prevent infiltration of
unwanted cells, molecules, bacteria, and viruses into the
CNS. It has been shown that both peripheral and
neuroinflammation can weaken the BBB, allowing
peripherally circulating factors, such as soluble, bloodderived plasma proteins [105], monocytes [106, 107],
leukocytes [108-110], and pathogens to more readily enter
the CNS [111] and thus, contribute to neuroinflammation.
Peripherally circulating cytokines can induce
upregulation of miR-155 in brain endothelial cells and
lead to the disruption of tight junctions between cells
[112]. Accumulating Aβ42 within the AD brain has been
shown to reduce miR-107 in brain endothelial cells and
lead to weakening of the BBB, the effects of which can be
reversed upon overexpression of miR-107 [113].
Additionally, during periods of neuroinflammation,
secretions from astrocytes can also weaken the BBB
[114], as can miR-34a-induced mitochondrial dysfunction
[115].
In order for immune cells to invade the CNS, they
must first adhere to the brain endothelium; this is
mediated by cellular adhesion molecules, namely ICAM1 and VCAM-1 expressed on vascular endothelial cells
(ECs). In response to TNF-α, IFN-γ, and IL-1, brain
microvascular endothelial cells (ECs) upregulate ICAM1 and VCAM-1 by 3- to 15-fold, thus enhancing immune
cell invasion. These cytokines may play a large role in the
infiltration of peripherally circulating leukocytes into the
CNS [95], while also contributing to progression of the
neuro-inflammatory response. Overexpressing miR-98
and let-7g* in brain microvascular endothelial cells
reduces monocyte adhesion and decreases BBB
permeability [116].
Aside from disease state, age can also heavily
influence the permeability and functional capacity of the
BBB [95, 111, 117]. Older adults and animals experience
reduced transport of key metabolic molecules, such as
glucose and choline, from the periphery into the CNS
[118], which can lead to impaired neurological
functioning. Just as in heightened inflammatory states,
when the integrity of the BBB has been compromised with
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age, it becomes more permeable, or leaky, allowing
peripheral substances entrance into the CNS [118].
Interestingly, there are areas of the CNS which lack a
blood-brain barrier (BBB). Regions such as the
circumventricular organs, ventricles, choroid plexus, and
meninges lack tight junctions between the vascular
endothelial cells; instead there are large fenestrations
between cells which allow for direct communication
between neurons and circulating blood [95, 119]. Not
surprisingly, these areas elicit an immune response similar
to what occurs in the periphery [93, 95].
Contributions of Microglia in the Immune Response
When foreign, peripheral substances cross the BBB,
microglia (which are commonly referred to as the resident
macrophages of the CNS) become activated. Under
normal physiological conditions, microglia were long
believed to be resting, or quiescent; however evidence
gathered over the past decade indicates that microglia are
constantly surveying the microenvironment for
disturbances, such as plaques, damaged neurons,
alterations in extracellular potassium levels, or intruders
like viruses or bacteria [120-124]. Like peripheral
macrophages, microglia can engulf and eliminate cellular
debris and present antigens to infiltrating T-cells [121].
Microglia play a pivotal role in the
neuroinflammatory response [reviewed by 125]. When
they become activated, they migrate towards the focal site
of inflammation within minutes [126]. Although restingstate microglia constitutively express immune regulatory
markers, their activation leads to a rapid upregulation of
these cellular immune markers, such as complement
receptors and major histocompatibility complex (MHC) II
antigens [87]. Additionally, activated microglia have also
been shown to secrete cytokines, chemokines,
complement factors, and free radicals [127-129].
Microglia also help to regulate the neuroimmune
response in chronic brain diseases, such as AD. For
example, in the normal brain, APP is constantly being
cleaved [87, 130], producing both soluble APPα (sAPPα)
and sAPPβ [131]. Soluble APPα is non-pathogenic and
does not accumulate, whereas sAPPβ can be processed to
β-amyloid 1-42 (Aβ42), and aggregate into fibrils and
plaques, characteristic of AD [131]. As extracellular
Aβ42 accumulates and begins to form plaques, it attracts
and activates microglia [132], which leads to the
observation of a barrier-like ring of microglia around the
plaque [133-135]. Aβ resides in the center of the plaque,
and other molecules, such as complement factors, have
also been observed within plaques [136]. Microglia
express complement C3a receptors (C3aR) and can
become activated upon receptor binding [137].
Complement-containing plaques are capable of inducing
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full blown complement cascades within the AD brain
[136, 138, 139], contributing to chronic local
inflammation.
Additionally, intracellular accumulations of Aβ42
have been observed within microglia [140], as Aβ42
molecules can be phagocytosed by microglia prior to
aggregation in a dose- and time-dependent manner [141].
In healthy brains, this process occurs constantly [142],
however in disease states, aggregated Aβ can be engulfed
but not easily broken down, as it can remain un-degraded
within the microglia for several days [143].
The neuroimmune response is a highly complicated
and dynamic process. Aside from traditional immune
interactions described above, miRs have also been
recently identified to play a role in microglial activation
and regulation in response to inflammation.
Understanding how miRs play a substantial role in
altering microglial activation, cytokine secretion, and
overall activity is an important factor for understanding
how neurodegenerative diseases progress. For a complete
review on this subject, see [144].
Briefly, activation of microglia to either the “proinflammatory” M1 (classical activation) or “antiinflammatory” M2 (alternative activation) phenotype
appears to be dependent on a network of miRs. For
example, LPS exposure shifts microglia towards the M1
phenotype, downregulates miR-Let-7a expression, and
subsequently leads to cell death [145]. Overexpression of
microglial miR-Let-7a altered the phenotypic activation
to M2, reduced apoptosis and nitrite production, increased
secretion of anti-inflammatory cytokines, and enhanced
production of brain-derived neurotrophic factor (BNDF)
[145]. Interestingly, miR-124 is highly expressed in
resting-state microglia but becomes significantly
downregulated when microglia take on the M2 phenotype
[146]. Overexpressing miR-124 in microglia prevents
microglial activation from even occurring [146].
Furthermore, miR-155 is classically regarded as a
pro-inflammatory miR, and is upregulated in M1
activated microglia after exposure to cytokines like TNFα and IFN-γ [147]. This has been shown to further
enhance cytokine release from microglial cells; however,
it has also been shown to induce IFN-β secretion, which
appears to activate an anti-inflammatory pathway [148,
149]. These data suggest that miR-155 may influence
early induction of the inflammatory response, while also
acting to regulate it downstream.
As previously discussed, inflammaging is a concept
in which the immune system shifts towards a proinflammatory state over the course of aging. Interestingly,
yet not unsurprisingly, inflammaging seems to influence
microglia and their capacity to react properly to brain
insult. Microglia undergo a shift towards a proinflammatory state, and contribute to dysfunctional or
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exaggerated responses to inflammation, thus creating an
unfavorable environment for neurons [as reviewed by
150, 151]. Studies investigating the protein and RNA
profiles of microglia in mice at different ages indicate that
age and sex do appear to play a role in expression patterns,
and that polarization towards the M1 phenotype occurs at
12 months of age [152]. Furthermore, as reviewed by
Spittau [153], several “hallmarks” of aging microglia
have been described, including upregulation of TLRs,
pro-inflammatory cytokines, and increased reactivity
upon stimulation. However, it should be mentioned that
M1 and M2 activation of microglia is not absolute; many
studies have found microglial activation to be on more of
a spectrum as opposed to two extreme activation states
[154, 155], and has led to the generation of many opinion
pieces voicing the same thoughts [156, 157].
By altering activation phenotype, alleviating cell
death, or preventing microglial activation altogether,
miRs have been implicated as potential therapeutic targets
for inflammatory diseases of the central nervous system.
Work in this area is ongoing, however many scientists
appear to draw conclusions from studies of miR
influences on macrophage activation and extrapolate
these data to microglia as well [158-160]. Although both
cell types are involved in the immune response, they are
inherently different, and studies need to replicate findings
from macrophages in microglia before any conclusive
interpretations can be drawn.
Aging and Inflammation
Human aging is characterized by chronic, low-grade
systemic
inflammation,
which
occurs
during
physiological aging in the absence of overt infection; this
phenomenon has been termed as “inflammaging.” [161].
Inflammaging is a highly significant risk factor for the
development and progression of age-related conditions,
including cardiovascular disease, type 2 diabetes mellitus
and neurodegenerative diseases [161]. The inflammatory
response comprises complex biological reactions that
require a fine-tuned integration between a range of
immune system cells and an extensive network of
biomolecules, which until recently had been thought to be
largely cytokines. However, identification of a vast
repertoire of miRs in the mammalian genome has
completely revolutionized our understanding of most
cellular processes, including inflammation.
Age-associated chronic inflammation has also been
attributed to the accumulation of senescent cells with a
pro-inflammatory secretory phenotype [162]. Induced
expression of miR-146a in human umbilical and coronary
endothelium during replicative senescence indicates that
TLR/NF-κB activation and cell senescence can be
modulated by miR-146a [163]. Arterial inflammaging
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highly contributes to cardiovascular morbidity and
mortality. miR-34a has been implicated in tissue aging
and endothelial progenitor cell senescence [164].
Furthermore, miR34a induces vascular smooth muscle
cellular senescence in aortas of old mice by inducing the
transcriptional expression of a subset of pro-inflammatory
factors [32].
miRs and Neurons
Neuronal growth and differentiation relies heavily on
proper miR signaling pathways. For example, in order for
newly born neurons to mature and differentiate into
granule cells within the hippocampus, miR-132 is
required for proper dendritic formation [165]. Further
discussion of miR roles in neuronal development and
maturation is beyond the scope of this review, but these
topics have been previously reviewed elsewhere [166,
167].
miRs have been implemented in the formation of
memories, which relies heavily on hippocampal synaptic
plasticity. Cognitive impairments such as diminished
memory formation and recollection are among the first
symptoms observed in many neurodegenerative diseases
such as mild cognitive impairment (MCI) and AD, and
can be implemented in other diseases like Parkinson’s
disease (PD) and multiple sclerosis (MS) at a later stage
of disease progression.
In order for long-term memories to be created,
alterations in the synapse must occur. These changes
require the presence of readily available proteins, or
protein synthesis at or near the synapse; this requires the
presence of mRNA. The presence of mRNAs encoding for
local protein synthesis (as opposed to somatic protein
synthesis, followed by transport to the synapse) is now
widely accepted [extensively reviewed in 168].
Within the last decade, evidence has surfaced that
miRs targeting mRNA of important synaptic forming
proteins are present in dendritic spines. As such, if protein
translation is being repressed by miRs within a postsynaptic density, then proper synaptic change will not
occur, leading to impaired memory formation [169].
Limk1 is a protein kinase present in dendritic spines that
controls their development [170]. miR-134 has been
shown to negatively regulate Limk1 mRNA translation at
the synapse; until the appropriate external stimulus is
received by the neuron, Limk1 protein synthesis is
repressed [170].
miRs and Brain Diseases/Injury
Many diseases that plague our society stem from yet
unknown etiologies. Recent developments in human
genomics better allow us to understand disease-related
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alterations in DNA, RNA, and proteins at a molecular
level. The newly emerging field of bioinformatics sheds a
great deal of light on the regulation of miRs and the
proteins they effect. Understanding how levels of specific
miRs, or clusters of miRs, change in response to various
stressors, inflammatory markers, and disease states could
provide promising potential therapeutic targets for future
medical implementation. A large portion of work
regarding miRs and disease focuses on characterizing
miR profiles; for example, identifying and understanding
miR panels prior to the onset and during the progression
of AD. Identifying a panel of miRs and their gene targets
could illuminate specific pathways that are implicated in
disease development and progression, allowing us to
better understand specific diseases and create novel
therapeutics for them.
miRs and Alzheimer’s Disease
AD is a neurodegenerative disease characterized by
memory impairment, confusion, anxiety, and depression,
and is evidenced by brain atrophy, ventricle enlargement,
Aβ42 plaques, and hyperphosphorylated tau. Presently, it
is the 6th leading cause of death in the United States and
there is no cure or effective treatment for the disease
[https://www.alz.org/facts/; 171]. The cause of this
disease and the driving force behind its progression
appears to be very complex and may rely heavily on
genetic risk factors and regulatory mechanisms, which
may easily implicate miRs in disease onset and
progression.
AD is thought to be preceded by MCI. It has been
widely shown that adults diagnosed with MCI experience
chronic brain vasculature hypoperfusion, which can lead
to increases in Aβ deposits and death receptor-6 (DR6)
protein, activation of caspases-3 and -6, and dendrite
degeneration [172]. The presence of DR6 has been
implicated with neuronal loss and dendritic degeneration.
miR-195 targets DR6 mRNA; upregulation of this miR
has been demonstrated to reduce translation of DR6
protein, and subsequently diminish the loss of both
dendrites and neurons [172]. AD-linked neuronal loss and
impaired neurite differentiation has also been linked to
upregulation of miR-211-5p; and these effects were found
to be exacerbated in the presence of extracellular Aβ
[173].
miRs have been shown to influence the expression
and aggregation of the brain-specific microtubuleassociated protein, tau. Both clinical evidence and
transgenic animal models indicate that anxiety is a
common psychiatric symptom experienced in AD [174,
175], and it is likely due to tau dysregulation [176].
Anxiety may be the result of upregulated miR-92a in AD
brains; one target of this miR is vGAT, which is

Aging and Disease • Volume 10, Number 2, April 2019

microRNAs in Aging and Disease

responsible for loading GABA, the main inhibitory
neurotransmitter, into secretory vesicles [177].
Dysregulation of GABA signaling has been thought to
contribute to anxiety, as neurons are left in an unregulated,
overexcited state. Both the overexpression of vGAT and
the administration of a miR-92a antagomir reduced
anxiety-related behaviors in a mouse model of
overexpressed human tau [177], suggesting a crucial role
for miR-92a in the GABA secretory pathway, with
subsequent effects on anxiety behavior.
Our lab has recently demonstrated that miR-34a is
significantly upregulated within the temporal cortex of
post-mortem AD brains, as well as the temporal cortices
and hippocampi of a triple transgenic mouse model of AD
(3xTgAD) [41]. Additionally, overexpression of miR-34a
in primary neurons leads to subsequent mitochondrial
dysfunction, as indicated by reduced mitochondrial
respiration and ATP production [41]. A key observation
in AD patients is a reduction in glucose metabolism;
abhorrent upregulation of miR-34a may be a main
contributor to this observed phenomenon within the
hippocampus.
miRs such as miR-132 and miR-212 have been
implicated in the regulatory capacity of neuronal nitric
oxide synthase (NOS1) in humans; these miRs are
downregulated in AD and other tauopathies [178]. Due to
the downregulation of miR-132 and miR-212, NOS1 is
increased in these diseases and activates a deleterious
cascade, which results in tau hyperphosphoyrlation and
neuronal cell death [178]. Secretion of miR-132 in
neuron-derived exosomes to endothelial cells regulates
vascular endothelial cadherin (VE-cadherin/Cdh5)
protein expression by targeting eukaryotic elongation
factor 2 kinase (eef2k) [179]. In circumstances where
levels of miR-132 are decreased, Cdh5 protein levels
decrease, and BBB integrity becomes compromised
[179].
In search of a potential biomarker for AD, many
groups have profiled miR expression from patients’ blood
and blood components (plasma and serum) [reviewed by
180] and post-mortem brains [reviewed by 181]. Across
multiple investigators and sample types, the most
consistently identified miRs seem to be miR-9, miR-125b,
miR-39, miR-155, and miR-146a. Identifying biomarkers
of AD has great potential for disease diagnostics, however
it becomes very complicated when levels of miRs change
so drastically across sample types, detection methods, and
labs. For example, while one group observed a
downregulation of miR-9 in AD serum when compared to
controls, using qRT-PCR [182], another group observed
miR-9 upregulation in AD serum compared to controls,
also using qRT-PCR [183]. Differential patterns in miR
expression convolute the ability to identify one or several
definite miR biomarkers for non-invasively detecting AD.
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However, it is clear that miR expression is altered in AD
when compared to age-matched controls, indicating that
miRs must be influencing disease progression in some
manner.
miRs and Parkinson’s Disease
Parkinson’s disease (PD) is a progressive neurological
disorder that affects movement in its early stages, and
cognitive function in later stages [184]. The etiology of
the disease is not well understood, however like most
neurodegenerative diseases it is thought that the interplay
between genetics and environmental factors leads to
disease development. In PD, neurons within the substantia
nigra die, and physical symptoms such as tremors or
rigidity occur. As the disease progresses, patients often
experience depression and anxiety, sleep disturbances,
and dementia.
The family of miR-29s (miR-29a, b, and c) was found
to be significantly downregulated in PD patients when
compared to controls; these miRs have been implicated in
neuronal proliferation, differentiation, plasticity, and
survival, and their downregulated expression may lead to
subsequent loss of neuronal viability in PD patients [185].
In addition to miR-29, miR-1, miR-22, miR-133b,
and miR-433 have also been found to be significantly
downregulated in PD patients when compared to controls
[186-188]. Tubulin polymerization-promoting protein
(TPPP/p25) is enriched in neurological brain lesions and
its accumulation may contribute to alpha-synuclein
aggregation in PD brains; miR-1 targets TPPP/p25,
therefore reductions of miR-1 can lead to pathological
overexpression of TPPP/p25 and subsequent alphasynuclein aggregates [186]. In an in vitro cell culture
model of PD, miR-22 was shown to be downregulated in
PD-induced cells, and was associated with cell death and
stunted cell proliferation; overexpression of miR-22
attenuated these effects and enhanced cellular survival
and proliferation [189].
Ceruloplasmin is a key enzyme in regulating iron
metabolism. In PD, it has been shown to be significantly
reduced in serum and CSF compared to healthy controls;
its reduced presence may enhance the deposition of iron
in the substantia nigra of PD patients [190]. Recent work
suggests that miR-133b downregulation modulates
ATP7B gene expression, and indirectly alters
ceruloplasmin levels leading to subsequent nigral iron
deposition [190]. Work from other labs however does not
reveal differential expression of miR-133b in substantia
nigra dopamine neurons when compared to age-matched
controls [191], or in dopaminergic neuron development
[192], so further work is required to parse out the potential
influences of miR-133b in PD. Furthering this point,
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another lab studied miR-433 variations in PD patients and
found no differences from control patients [193].
In PD patients, compared to controls, has-miR-46395p was found to be significantly upregulated, leading to
downregulation of DJ-1 protein which has been shown to
cause oxidative stress and cell death [194]. The commonly
used model of induced PD is animals exposed to 1methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). In
vivo experiments have shown that after PD induction,
miR-124 levels are significantly reduced, and these results
were also observed in an in vitro MPTP-induced PD
induced model [195]. Subsequent analysis indicated that
miR-124 may play a protective role as its knockdown
leads to increased ROS and H2O2 production and
enhances expression of the calpain 1/p25/cdk5 protein
pathway, leading to neuronal cell death [195].
Additionally, miR-181c has been identified as
significantly downregulated in blood and brain samples of
PD patients. In an in vitro model of PD, this dysregulation
was also observed and was associated with neuronal
apoptosis, ROS, and caspcase-3 activation [196].
miRs and Stroke
Strokes occur when a cerebral artery is blocked (ischemic
stroke; 87% of cases) or ruptures (intracerebral or
subarachnoid hemorrhage; 10 and 3% of cases,
respectively), resulting in a loss of blood flow to the brain
area supplied by that artery [197]. Stroke is the 5th leading
cause of death, and a leading cause of long-term disability,
with limited treatment options. Although proven effective
if administered to an eligible patient population, the
therapeutic window of recombinant tissue plasminogen
activator (tPA), the most widely adopted thrombolytic
agent, is exceptionally short (3-4.5 hours from symptom
onset), due to the increased risk of cerebral hemorrhage
when given after that time point. There is a critical need
to develop rapid and accurate diagnostic tools, as well as
novel therapeutic interventions for the treatment of
ischemia; miRs hold great promise for both.
During stroke, as cells deprived of oxygen and
glucose begin to die, an inflammatory response is initiated
within the brain. In response, activated microglia begin
secreting many factors, some of which prompt further
neuronal cell death, such as TNF-α and IL-1β [198]. As
TNF-α upregulation occurs, there is a pronounced
downregulation of miR-181c in activated rat microglial
cells; this relationship can be reversed by transfecting
microglia with miR-181c, thus decreasing levels of TNFα, reducing inflammation, and subsequently reducing
neuronal cell death [198]. Interestingly, another group
found increases in levels of all miRs of the 181 family (ad) post-stroke within the ischemic core, but decreases in
these same miRs in the penumbra region [199]. By

341

Sarkar SN., et al

knocking down levels of miR-181a, cell death in response
to oxygen/glucose deprivation was reduced [199].
Similarly, in male rats subjected to bilateral carotid artery
occlusion, miR-181a levels were increased relative to
sham animals; treatment of stroke animals with a miR181a antagomir increased Bcl-2 levels and decreased
neuronal loss [200]. Microglial activation, and subsequent
cytokine release, has been shown to be inhibited by
knockdown of miR-377 [201]. Targets of this miR include
EGR2 and VEGF, which influence inflammation and
angiogenesis, respectively. In a rat MCAO stroke model,
knocking down miR-377 reduced ischemic infarct size by
reducing inflammation mediated by microglial activation,
and promoting angiogenesis, thus leading to better stroke
outcomes [201].
Additionally, favorable stroke outcomes rely partially
on the integrity of the BBB post-insult. Recent data
implicate significant post-stroke decreases of miR-122 in
whole blood of both stroke patients and animal models,
and the possibility that this miR plays a role in mediating
stroke outcomes [202]. Targets of miR-122 include
proteins that affect cell adhesion and leukocyte
extravasation. When miR-122 was administered into the
blood, lower infarct volume and better neurological
outcomes were observed as compared to when it was
directly injected into brain ventricles, indicating that this
miR is likely affecting CNS leukocyte invasion via
peripheral mechanisms rather than directly influencing
CNS tissue [202]. In the stroke-prone spontaneously
hypertensive rat model, it was shown that prior to onset of
stroke, levels of miR-122 within the brain are decreased
substantially. Additionally, vascular endothelial cells
showed heightened levels of inflammation and death,
leading to degradation of the BBB, however these
responses were attenuated after exposure to miR-122
[203]. Together, these data suggest that miR-122 acts
through the blood to improve the integrity of endothelial
cells comprising the BBB.
In the same vein, miR-126 and miR-126* also appear
to regulate leukocyte adhesion and infiltration across the
BBB [204]. These miRs are downregulated in response to
pro-inflammatory cytokines, such as TNF-α, which tend
to be upregulated in disease states. When they are
downregulated, VCAM1 and E-selectin levels are
increased, respectively, and leukocyte adhesion
significantly increases [204], which can lead to enhanced
leukocyte extravasation into the brain, thus worsening
patient outcomes. Additionally, miR-126 has been shown
to facilitate vascular remodeling after cardiovascular
insult, such as stroke. In a mouse line with conditional
knock-out of miR-126 in endothelial cells, knockout mice
fared worse than controls post-stroke, exhibiting higher
levels of inflammation and cardiac hypertrophy [205].
Stroke-induced miR-126 downregulation appears to play
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a large role in outcomes related to inflammation and
overall cardiovascular health after insult.
Other examples of miRs thought to have important
roles in mediating ischemic stroke outcomes include miR146a/miR-146b [206], miR-9 [207], and miR-130b [208].
Upregulating the expression levels of miR-146a and miR146b was shown to promote proliferation and
angiogenesis of endothelial progenitor cells after acute
ischemic stroke in mice [206]. While not yet directly
linked to stroke, miR-9 has been shown to enhance neural
stem cell proliferation, as well as angiogenesis, which
could potentially work to enhance post-stroke CNS repair
[207]. Interestingly, miR-130b exerts its protective effects
by regulating aquaporin 4 (AQP4) in astrocytes [208].
Levels of AQP4 have been shown to be significantly
upregulated in astrocytes post-stroke and are associated
with enhanced cerebral edema [209]. Post stroke levels of
miR-130b are significantly reduced, and continue to
decrease over 24-48 hours, allowing for increased
translation of AQP4 [208]. By transfecting primary
astrocytes with miR-130b mimics, the deleterious effects
of oxygen/glucose deprivation (OGD) were attenuated
and expression of AQP4 was inhibited [208].
Additionally, miR-29 appears to be associated with cell
survival/death pathways. miR-29b levels are increased at
24 hours following 90 min tMCAO in rat brains [210] and
found to promote cell death. In rats, miR-29c
overexpression reduced anti-apoptotic proteins, increased
infarct, and negatively impacted neurological outcomes
[211]. Interestingly, in mice, miR-29b [212] and miR-29c
[213] levels are reduced in brain and overexpression
reduces lesion volume, edema, blood brain barrier
disruption, and cell death.
The severity of stroke outcomes also relies on the
extent of injury caused by cerebral reperfusion after blood
flow has been restored. miR-323 has been shown to be
upregulated in response to OGD in a cell model of
ischemic stroke and is associated with apoptosis by
reducing levels of Brain protein I 3 (BRI3) [214]. In
response to stroke, miR-30a has been shown to be
upregulated within the infarct core, but downregulated in
the peri-infarct area after reperfusion, which appears to be
neuroprotective [215]. miR-30a targets the mRNA of
Beclin-1, which is a protein that mediates neuronal
autophagy; when levels of Beclin-1 are decreased,
neuronal death is enhanced as the cells are unable to
adequately degrade damaged internal molecules created
in response to OGD [215].
After cerebral ischemia, expression of miR-124 is
significantly downregulated in the brain [216]. With
constant intracerebroventricular infusion of a miR-124antagomir prior to MCAO, animals had better
neurological outcomes post-stroke, and smaller infarct
areas [216]. These data indicate that miR-124 may be an
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important player in reducing negative stroke outcomes in
both mice [146, 217, 218] and rats [216]. However, other
reports indicate that in mice experiencing tMCAO, brain
miR-124 levels increased following stroke and
experimentally-induced overexpression was associated
with neuroprotective effects and beneficial outcomes
[219, 220]. These conflicting reports exemplify the
complexity of miR-mRNA interactions in response to
ischemic stroke.
With regard to sex, it is as yet unclear what role it
plays in miR changes in brain trauma. Work done by the
Sohrabji and McCullough groups has noted a key role of
sex and sex hormones in the context of experimental
stroke. For example, sex differences have been noted for
post-stroke brain levels of miR-23a, a target of which is
X-linked inhibitor of apoptosis (XIAP), such that miR-23
was decreased in males but increased in females [221].
Interestingly, inhibition of XIAP significantly increased
infarct volume in females but not males, providing
evidence for sex-specific effects of stroke on miRs. As
well, antagomir treatment of miR-1 and –Let7f, miRs that
target the IGF-1 pathway, was beneficial among adult
female, gonadally intact rats but not males or
ovariectomized females [222]. It should be noted that the
majority of studies assessing miR level changes in stroke
are conducted in male rodents and in many reports, there
was no documentation of, nor control for, endogenous
reproductive hormone levels, a potential critical
biological factor given the known neuroprotective actions
of estrogen and progesterone in the context of stroke and
other CNS pathologies. Future investigations specifically
considering sex as a biological variable in the miRassociated response in stroke are warranted.
Despite this, miRs have great potential to serve as
easily accessible peripheral biomarkers for stroke [223,
224]. In preclinical studies where miRs were evaluated in
both brain and peripheral tissues following stroke, while
tissue specific changes in some miRs were noted, others
were similarly dysregulated in both brain and blood [225,
226]. The ability to differentiate brain injury type and
stage, especially when the etiology of injury or stage of
progression is unknown, is of important clinical relevance
to the treatment of stroke given the limited time window
with which tPA can be administered following an
ischemic event, and given that it is contraindicated for
hemorrhagic stroke [227]. This could potentially allow for
rapid, accurate diagnostics when stroke patients enter the
emergency department as opposed to requiring lengthy,
expensive imaging techniques to confirm stroke
occurrence. Unfortunately, as is the case in AD, different
labs identify varying miR profiles. These differences
could be due to a number of factors which could influence
relative amounts of miRs detected in patient samples,
including the location of the stroke, the length of time that
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passes between symptom onset and sample collection,
treatment interventions, and the health status/history of
the patient.
miR Disease Therapeutics
As alluded to in each of the preceding sections discussing
miRs and specific diseases, scientists and clinicians are
heavily invested in the promise of using miRs as potential
biomarkers for particular diseases. Initially, miRs seem
like promising candidates for disease identification
because of their relative stability in the blood [228], as
bound by lipoproteins and ribonucleoprotein complexes,
or encapsulated within microvesicles and exosomes [229,
230], preventing their degradation by RNases. However,
the issue of utilizing this small RNA species as a
biomarker from disease arises in the heterogeneity within
an individual disease, and across hospitals and
laboratories. These confounding findings could be due to
a number of variables such as timing of sample collection
in regards to disease progression and therapeutic
interventions, RNA isolation techniques, and
quantification methods. More stringent guidelines are
required from the scientific community before differential
findings can be viewed as solely disease-relevant
variations.
Aside from biomarkers, the use of miRs has been
viewed as potential therapeutic strategies. Personalized
medicine is seeing more and more discussion within the
medical field, and identifying genetic variations caused by
diseases could allow for direct genetic targeting in
medicine. For example, a patient with AD, found to
overexpress a specific miR, could be administered an
antagonist for the miR in question. Conversely, if a miR
was observed in significantly decreased levels, the patient
could be supplemented with synthetic oligonucleotide
strands to mimic the miR.
An alternative approach for keeping overexpressed
miRs in check would be to focus on miR recognition
elements (MREs) on target mRNA, which can sponge
miRs, therefore preventing their interaction with
functional mRNA molecules [231, 232]. For example,
ribonuclease P RNA Component H1 (Rpph1) competes
with CDC42 (a Rho GTPase which enhances dendritic
spine
formation)
for
miR-326-3p/miR-330-5p.
Overexpression of Rpph1 results in increased dendritic
spine formation, as more CDC42 is able to be translated
[232]. Theoretically, this intervention strategy could be
applied in diseases characterized by reductions in
dendritic spines, thus enhancing synaptic plasticity.
These types of disease interventions are currently in
the early stages of exploration [233], however it is a very
complex therapeutic strategy and will most likely take
years to develop efficient and safe treatment methods. A
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main issue facing the field is that many of the predicted
targets of altered miRs are currently unknown, and it is
important to remember that a single miR can target many
different mRNAs, and a single mRNA can be targeted by
many different miRs. Preventing the aberrant function of
a specific miR implicated in a disease-related pathway
may indeed alleviate the issue associated with the targeted
cascade, however, because of their complexity, other
miR-mRNA interactions may be subsequently altered and
have deleterious off-target effects.
Lastly, evaluating miR changes in age-related
neurological conditions should be assessed in the context
of the treatment regimens typically employed and known
to induce neurobeneficial effects (i.e. tPA and stroke), as
these considerations will be critical to understanding the
cellular mechanisms of actions of current therapeutic
treatments, and developing more specific interventions.
Despite these remaining challenges, as we have discussed
above within several neurological disease conditions,
several patterns in alterations of miRs have emerged that
may represent viable candidates for use as biomarkers for
injury severity and/or disease progression, and possibly
serve as novel therapeutic targets towards which
neurorestorative treatments can be directed. Future
research will continue to clarify these remaining
questions.
Conclusion and Future Perspectives
Extensive research to identify functional roles of miR
target genes has provided insights into the molecular
mechanisms by which aging processes are regulated at the
cell, tissue, organ, and organism level. Further,
determination of aging-related miRs have yielded a better
understanding of the connection between the processes of
aging and the onset of aging-related diseases. Aging
phenotypes are known to be interconnected; for example,
telomere attrition is a characteristic of cellular senescence,
which is connected to activation of the DNA damage
response and acquired senescence associated secretory
phenotype (SASP). Likewise, a number of miRs are
regulators of overlapping hallmarks of aging, shown in
Figure 1. Recent studies have also indicated that a single
miR, miR-34a, correlates with aging of both mice and
humans; affording the consideration of miR-34a to be a
biomarker for the aging brain and heart.
In the aging heart, miR-34a induces telomere
attrition, DNA damage responses, cardiomyocyte
apoptosis, and deteriorates recovery after acute
myocardial infarction. In aging brains and in the brains of
patients with AD, miR-34a targets genes involved in
neural activity-dependent grey and white matter
plasticity,
activity-dependent
angiogenesis,
neurodegeneration, and memory impairment. Aging-
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induced heart and brain specific miRs, like miR-34a, may
be involved in the pathogenesis of cardiovascular diseases
and cognitive dysfunction. Although we still do not fully
understand the molecular mechanisms by which aging
induces miR expression in a specific tissue, it has been
reported that human miR-34a promoter contains the p53,
NF-kB, and STAT3 transcription factor binding sites [41],
which can be activated in aging tissues due to increased
ROS and inflammaging. Thus, molecules that alter the
function or abundance of specific miRs e.g., miR-34a,
represent a new target strategy for treating human
diseases.
Recent progress in the development of effective
strategies to block miRs suggest that anti-miR drugs may
soon be used in the clinic. The major strategy for
inhibiting miR function is the use of antisense
oligonucleotides
of
mature
miRs.
Antisense
oligonucleotides used in many preclinical stages are of
three types: i), 2’-O-methyl (2’-Ome), ii) 2- methoxy
methyl (2’MOE), iii) 2, 4-methyl locked nucleic acid (24-LNA). Currently, the development status of most
miRNAs is at the preclinical and target peripheral
diseases. miR-122 is being applied for Hepatitis C Virus
(HCV), miR-21 for renal fibrosis, miR-33 for
atherosclerosis, miR-92 for peripheral artery disease, and
miR-15 for myocardial infarction, using antisense
oligonucleotides for inhibition of respective miRs
function. In initial clinical assessment of miR
therapeutics, a miR-34a mimic is in a phase I trial for the
treatment of primary liver cancer. Also, Santaris Pharma
is studying miR-122 antisense oligo in a phase Ia clinical
trial for the treatment of hepatitis C. A new strategy is miR
sponge nanoparticles. The miR sponge nanoparticle
downregulates the targeted miR and possesses multiple
complementary sites to the targeted miRs [234]. Targeted
delivery of anti-miR oligonucleotides remains difficult for
many organs, including the brain. Thus, for effective and
targeted delivery of anti-miR oligonucleotides to a
specific tissue, new technologies are required.
Acknowledgments
Research presented herein was supported by NIH grants
P20 GM109098, P01 AG027956, U54 GM104942, and
T32 AG052375.
References
[1]
[2]
[3]

Lopez-Otin C, Blasco MA, Partridge L, Serrano M,
Kroemer G (2013). The hallmarks of aging. Cell, 153:
1194-1217
Ames BN, Shigenaga MK, Hagen TM (1993).
Oxidants, antioxidants, and the degenerative diseases
of aging. Proc Natl Acad Sci U S A, 90: 7915-7922
Beal MF (1995). Aging, energy, and oxidative stress in

344

Sarkar SN., et al

[4]
[5]

[6]

[7]

[8]

[9]

[10]

[11]

[12]

[13]
[14]

[15]

[16]
[17]
[18]
[19]

neurodegenerative diseases. Ann Neurol, 38: 357-366
Finkel T, Serrano M, Blasco MA (2007). The common
biology of cancer and ageing. Nature, 448: 767-774
Jousilahti P, Vartiainen E, Tuomilehto J, Puska P
(1999). Sex, age, cardiovascular risk factors, and
coronary heart disease: a prospective follow-up study
of 14 786 middle-aged men and women in Finland.
Circulation, 99: 1165-1172
Lindsay J, Laurin D, Verreault R, Hebert R, Helliwell
B, Hill GB, et al. (2002). Risk factors for Alzheimer's
disease: a prospective analysis from the Canadian
Study of Health and Aging. Am J Epidemiol, 156: 445453
Katsimpardi L, Litterman NK, Schein PA, Miller CM,
Loffredo FS, Wojtkiewicz GR, et al. (2014). Vascular
and neurogenic rejuvenation of the aging mouse brain
by young systemic factors. Science, 344: 630-634
Loffredo FS, Steinhauser ML, Jay SM, Gannon J,
Pancoast JR, Yalamanchi P, et al. (2013). Growth
differentiation factor 11 is a circulating factor that
reverses age-related cardiac hypertrophy. Cell, 153:
828-839
Sinha M, Jang YC, Oh J, Khong D, Wu EY, Manohar
R, et al. (2014). Restoring systemic GDF11 levels
reverses age-related dysfunction in mouse skeletal
muscle. Science, 344: 649-652
Villeda SA, Plambeck KE, Middeldorp J, Castellano
JM, Mosher KI, Luo J, et al. (2014). Young blood
reverses age-related impairments in cognitive function
and synaptic plasticity in mice. Nat Med, 20: 659-663
Villeda SA, Luo J, Mosher KI, Zou B, Britschgi M,
Bieri G, et al. (2011). The ageing systemic milieu
negatively regulates neurogenesis and cognitive
function. Nature, 477: 90-94
Weilner S, Schraml E, Redl H, Grillari-Voglauer R,
Grillari J (2013). Secretion of microvesicular miRNAs
in cellular and organismal aging. Exp Gerontol, 48:
626-633
Kang HJ, Kawasawa YI, Cheng F, Zhu Y, Xu X, Li M,
et al. (2011). Spatio-temporal transcriptome of the
human brain. Nature, 478: 483-489
Mertens J, Paquola ACM, Ku M, Hatch E, Bohnke L,
Ladjevardi S, et al. (2015). Directly reprogrammed
human neurons retain aging-associated transcriptomic
signatures and reveal age-related nucleocytoplasmic
defects. Cell Stem Cell, 17: 705-718
Persengiev SP, Kondova, II, Bontrop RE (2012). The
Impact of MicroRNAs on Brain Aging and
Neurodegeneration. Curr Gerontol Geriatr Res, 2012:
359369
Kozomara A, Griffiths-Jones S (2014). miRBase:
annotating high confidence microRNAs using deep
sequencing data. Nucleic Acids Res, 42: D68-73
Harries L (2014). MicroRNAs as mediators of the
ageing process. Genes, 5: 656
Jung HJ, Suh Y (2012). MicroRNA in aging: From
discovery to biology. Curr Genomics, 13: 548-557
Mah SM, Buske C, Humphries RK, Kuchenbauer F
(2010). miRNA*: a passenger stranded in RNAinduced silencing complex? Crit Rev Eukaryot Gene

Aging and Disease • Volume 10, Number 2, April 2019

microRNAs in Aging and Disease

[20]

[21]
[22]

[23]

[24]
[25]

[26]

[27]

[28]

[29]

[30]

[31]

[32]

[33]

Expr, 20: 141-148
Dasika GK, Lin SC, Zhao S, Sung P, Tomkinson A,
Lee EY (1999). DNA damage-induced cell cycle
checkpoints and DNA strand break repair in
development and tumorigenesis. Oncogene, 18: 78837899
Wang Y, Taniguchi T (2013). MicroRNAs and DNA
damage response: implications for cancer therapy. Cell
Cycle, 12: 32-42
Hoch NC, Hanzlikova H, Rulten SL, Tetreault M,
Komulainen E, Ju L, et al. (2017). XRCC1 mutation is
associated with PARP1 hyperactivation and cerebellar
ataxia. Nature, 541: 87-91
Lee Y, Katyal S, Li Y, El-Khamisy SF, Russell HR,
Caldecott KW, et al. (2009). The genesis of cerebellar
interneurons and the prevention of neural DNA
damage require XRCC1. Nat Neurosci, 12: 973-980
Barzilai N, Huffman DM, Muzumdar RH, Bartke A
(2012). The critical role of metabolic pathways in
aging. Diabetes, 61: 1315-1322
Rivas DA, Lessard SJ, Rice NP, Lustgarten MS, So K,
Goodyear LJ, et al. (2014). Diminished skeletal
muscle microRNA expression with aging is associated
with attenuated muscle plasticity and inhibition of
IGF-1 signaling. FASEB J, 28: 4133-4147
Hung TM, Ho CM, Liu YC, Lee JL, Liao YR, Wu YM,
et al. (2014). Up-regulation of microRNA-190b plays
a role for decreased IGF-1 that induces insulin
resistance in human hepatocellular carcinoma. PLoS
One, 9: e89446
Elia L, Contu R, Quintavalle M, Varrone F, Chimenti
C, Russo MA, et al. (2009). Reciprocal regulation of
microRNA-1 and insulin-like growth factor-1 signal
transduction cascade in cardiac and skeletal muscle in
physiological and pathological conditions. Circulation,
120: 2377-2385
Shan ZX, Lin QX, Fu YH, Deng CY, Zhou ZL, Zhu
JN, et al. (2009). Upregulated expression of miR1/miR-206 in a rat model of myocardial infarction.
Biochem Biophys Res Commun, 381: 597-601
Patel M, Gomez NC, McFadden AW, Moats-Staats
BM, Wu S, Rojas A, et al. (2014). PTEN deficiency
mediates a reciprocal response to IGFI and mTOR
inhibition. Mol Cancer Res, 12: 1610-1620
Satoh A, Brace CS, Rensing N, Cliften P, Wozniak DF,
Herzog ED, et al. (2013). Sirt1 extends life span and
delays aging in mice through the regulation of Nk2
homeobox 1 in the DMH and LH. Cell Metab, 18: 416430
Menghini R, Casagrande V, Cardellini M, Martelli E,
Terrinoni A, Amati F, et al. (2009). MicroRNA 217
modulates endothelial cell senescence via silent
information regulator 1. Circulation, 120: 1524-1532
Badi I, Burba I, Ruggeri C, Zeni F, Bertolotti M,
Scopece A, et al. (2015). MicroRNA-34a induces
vascular smooth muscle cells senescence by SIRT1
downregulation and promotes the expression of ageassociated pro-inflammatory secretory factors. J
Gerontol A Biol Sci Med Sci, 70: 1304-1311
Hartl FU, Bracher A, Hayer-Hartl M (2011).

345

Sarkar SN., et al

[34]

[35]
[36]

[37]

[38]

[39]

[40]
[41]

[42]
[43]

[44]

[45]

[46]

[47]

Molecular chaperones in protein folding and
proteostasis. Nature, 475: 324-332
Powers ET, Morimoto RI, Dillin A, Kelly JW, Balch
WE (2009). Biological and chemical approaches to
diseases of proteostasis deficiency. Annu Rev
Biochem, 78: 959-991
Koga H, Kaushik S, Cuervo AM (2011). Protein
homeostasis and aging: The importance of exquisite
quality control. Ageing Res Rev, 10: 205-215
Sweeney P, Park H, Baumann M, Dunlop J, Frydman
J, Kopito R, et al. (2017). Protein misfolding in
neurodegenerative diseases: implications and
strategies. Transl Neurodegener, 6: 6
Stetler RA, Gan Y, Zhang W, Liou AK, Gao Y, Cao G,
et al. (2010). Heat shock proteins: cellular and
molecular mechanisms in the central nervous system.
Prog Neurobiol, 92: 184-211
Ren X-P, Wu J, Wang X, Sartor MA, Qian J, Jones K,
et al. (2009). MicroRNA-320 is involved in the
regulation of cardiac ischemia/reperfusion injury by
targeting Heat-Shock Protein 20. Circulation, 119:
2357-2366
Alvarez-Erviti L, Seow Y, Schapira AH, RodriguezOroz MC, Obeso JA, Cooper JM (2013). Influence of
microRNA deregulation on chaperone-mediated
autophagy and α-synuclein pathology in Parkinson's
disease. Cell Death &Amp; Disease, 4: e545
Boon RA, Iekushi K, Lechner S, Seeger T, Fischer A,
Heydt S, et al. (2013). MicroRNA-34a regulates
cardiac ageing and function. Nature, 495: 107-110
Sarkar S, Jun S, Rellick S, Quintana DD, Cavendish
JZ, Simpkins JW (2016). Expression of microRNA34a in Alzheimer's disease brain targets genes linked
to synaptic plasticity, energy metabolism, and resting
state network activity. Brain Res, 1646: 139-151
Frankel LB, Lund AH (2012). MicroRNA regulation
of autophagy. Carcinogenesis, 33: 2018-2025
Ganley IG, Lam DH, Wang JR, Ding XJ, Chen S, Jiang
XJ (2009). ULK1.ATG13.FIP200 complex mediates
mTOR signaling and is essential for autophagy.
Journal of Biological Chemistry, 284: 12297-12305
Hosokawa N, Sasaki T, Iemura S, Natsume T, Hara T,
Mizushima N (2009). Atg101, a novel mammalian
autophagy protein interacting with Atg13. Autophagy,
5: 973-979
Wu H, Wang FL, Hu SL, Yin C, Li X, Zhao SH, et al.
(2012). MiR-20a and miR-106b negatively regulate
autophagy induced by leucine deprivation via
suppression of ULK1 expression in C2C12 myoblasts.
Cell Signal, 24: 2179-2186
Wang ZY, Wang N, Liu PX, Chen QJ, Situ HL, Xie T,
et
al.
(2014).
MicroRNA-25
regulates
chemoresistance-associated autophagy in breast
cancer cells, a process modulated by the natural
autophagy inducer isoliquiritigenin. Oncotarget, 5:
7013-7026
Huang YP, Chuang AY, Ratovitski EA (2011).
Phospho-Delta Np63 alpha/miR-885-3p axis in tumor
cell life and cell death upon cisplatin exposure. Cell
Cycle, 10: 3938-3947

Aging and Disease • Volume 10, Number 2, April 2019

microRNAs in Aging and Disease
[48]

[49]

[50]

[51]

[52]

[53]

[54]
[55]

[56]

[57]

[58]
[59]
[60]

[61]

[62]
[63]

Tang B, Li N, Gu J, Zhuang Y, Li Q, Wang HG, et al.
(2012). Compromised autophagy by MIR30B benefits
the intracellular survival of Helicobacter pylori.
Autophagy, 8: 1045-1057
Menghini R, Casagrande V, Marino A, Marchetti V,
Cardellini M, Stoehr R, et al. (2014). MiR-216a: a link
between endothelial dysfunction and autophagy. Cell
Death & Disease, 5
Chatterjee A, Chattopadhyay D, Chakrabarti G (2014).
miR-17-5p Downregulation Contributes to Paclitaxel
Resistance of Lung Cancer Cells through Altering
Beclin1 Expression. Plos One, 9
Korkmaz G, le Sage C, Tekirdag KA, Agami R,
Gozuacik D (2012). miR-376b controls starvation and
mTOR inhibition-related autophagy by targeting
ATG4C and BECN1. Autophagy, 8: 165-176
Huang YP, Guerrero-Preston R, Ratovitski EA (2012).
Phospho-Delta Np63 alpha-dependent regulation of
autophagic signaling through transcription and microRNA modulation. Cell Cycle, 11: 1247-1259
Shi GD, Shi JG, Liu K, Liu N, Wang Y, Fu ZY, et al.
(2013). Increased miR-195 aggravates neuropathic
pain by inhibiting autophagy following peripheral
nerve injury. Glia, 61: 504-512
Frankel LB, Wen JY, Lees M, Hoyer-Hansen M,
Farkas T, Krogh A, et al. (2011). microRNA-101 is a
potent inhibitor of autophagy. Embo J, 30: 4628-4641
Ravikumar B, Imarisio S, Sarkar S, O'Kane CJ,
Rubinsztein DC (2008). Rab5 modulates aggregation
and toxicity of mutant huntingtin through
macroautophagy in cell and fly models of Huntington
disease. J Cell Sci, 121: 1649-1660
Kovaleva V, Mora R, Park YJ, Plass C, Chiramel AI,
Bartenschlager R, et al. (2012). miRNA-130a targets
ATG2B and DICER1 to inhibit autophagy and trigger
killing of chronic lymphocytic leukemia cells. Cancer
Research, 72: 1763-1772
Yang JR, Chen DP, He YN, Melendez A, Feng Z, Hong
Q, et al. (2013). MiR-34 modulates Caenorhabditis
elegans lifespan via repressing the autophagy gene
atg9. Age, 35: 11-22
Jegga AG, Schneider L, Ouyang XS, Zhang J (2011).
Systems biology of the autophagy-lysosomal pathway.
Autophagy, 7: 477-489
Lu T, Pan Y, Kao SY, Li C, Kohane I, Chan J, et al.
(2004). Gene regulation and DNA damage in the
ageing human brain. Nature, 429: 883-891
Eckert A, Schmitt K, Gotz J (2011). Mitochondrial
dysfunction - the beginning of the end in Alzheimer's
disease? Separate and synergistic modes of tau and
amyloid-beta toxicity. Alzheimers Res Ther, 3: 15
Ohta S, Ohsawa I (2006). Dysfunction of
mitochondria and oxidative stress in the pathogenesis
of Alzheimer's disease: on defects in the cytochrome c
oxidase complex and aldehyde detoxification. J
Alzheimers Dis, 9: 155-166
Femminella GD, Ferrara N, Rengo G (2015). The
emerging role of microRNAs in Alzheimer's disease.
Front Physiol, 6: 40
Nishino J, Kim I, Chada K, Morrison SJ (2008).

346

Sarkar SN., et al

[64]

[65]

[66]
[67]
[68]
[69]
[70]

[71]

[72]

[73]

[74]

[75]

[76]

[77]

[78]

Hmga2 promotes neural stem cell self-renewal in
young but not old mice by reducing p16Ink4a and
p19Arf expression. Cell, 135: 227-239
Xu N, Papagiannakopoulos T, Pan G, Thomson JA,
Kosik KS (2009). MicroRNA-145 regulates OCT4,
SOX2, and KLF4 and represses pluripotency in human
embryonic stem cells. Cell, 137: 647-658
Wagner W, Horn P, Castoldi M, Diehlmann A, Bork S,
Saffrich R, et al. (2008). Replicative senescence of
mesenchymal stem cells: a continuous and organized
process. PLoS One, 3: e2213
Choi YJ, Lin CP, Ho JJ, He X, Okada N, Bu P, et al.
(2011). miR-34 miRNAs provide a barrier for somatic
cell reprogramming. Nat Cell Biol, 13: 1353-1360
Eguchi T, Kuboki T (2016). Cellular reprogramming
using defined factors and microRNAs. Stem Cells Int,
2016: 7530942
Shammas MA (2011). Telomeres, lifestyle, cancer, and
aging. Curr Opin Clin Nutr Metab Care, 14: 28-34
Blackburn EH (2000). Telomere states and cell fates.
Nature, 408: 53-56
Mitomo S, Maesawa C, Ogasawara S, Iwaya T,
Shibazaki M, Yashima-Abo A, et al. (2008).
Downregulation of miR-138 is associated with
overexpression of human telomerase reverse
transcriptase protein in human anaplastic thyroid
carcinoma cell lines. Cancer Sci, 99: 280-286
Dinami R, Ercolani C, Petti E, Piazza S, Ciani Y,
Sestito R, et al. (2014). miR-155 drives telomere
fragility in human breast cancer by targeting TRF1.
Cancer Res, 74: 4145-4156
Jin K, Xiang Y, Tang J, Wu G, Li J, Xiao H, et al.
(2014). miR-34 is associated with poor prognosis of
patients with gallbladder cancer through regulating
telomere length in tumor stem cells. Tumour Biol, 35:
1503-1510
Raver-Shapira N, Marciano E, Meiri E, Spector Y,
Rosenfeld N, Moskovits N, et al. (2007).
Transcriptional activation of miR-34a contributes to
p53-mediated apoptosis. Mol Cell, 26: 731-743
Persengiev S, Kondova I, Otting N, Koeppen AH,
Bontrop RE (2011). Genome-wide analysis of miRNA
expression reveals a potential role for miR-144 in
brain aging and spinocerebellar ataxia pathogenesis.
Neurobiol Aging, 32: 2316 e2317-2327
Morita S, Horii T, Kimura M, Ochiya T, Tajima S,
Hatada I (2013). miR-29 represses the activities of
DNA methyltransferases and DNA demethylases. Int J
Mol Sci, 14: 14647-14658
Feng J, Zhou Y, Campbell SL, Le T, Li E, Sweatt JD,
et al. (2010). Dnmt1 and Dnmt3a maintain DNA
methylation and regulate synaptic function in adult
forebrain neurons. Nat Neurosci, 13: 423-430
Guan JS, Haggarty SJ, Giacometti E, Dannenberg JH,
Joseph N, Gao J, et al. (2009). HDAC2 negatively
regulates memory formation and synaptic plasticity.
Nature, 459: 55-60
Parra M (2015). Class IIa HDACs - new insights into
their functions in physiology and pathology. FEBS J,
282: 1736-1744

Aging and Disease • Volume 10, Number 2, April 2019

microRNAs in Aging and Disease
[79]

[80]

[81]
[82]
[83]

[84]

[85]
[86]
[87]

[88]

[89]

[90]
[91]

[92]
[93]
[94]

Madabhushi R, Gao F, Pfenning AR, Pan L,
Yamakawa S, Seo J, et al. (2015). Activity-induced
DNA breaks govern the expression of neuronal earlyresponse genes. Cell, 161: 1592-1605
Ramamoorthi K, Fropf R, Belfort GM, Fitzmaurice
HL, McKinney RM, Neve RL, et al. (2011). Npas4
regulates a transcriptional program in CA3 required
for contextual memory formation. Science, 334: 16691675
McKenzie IA, Ohayon D, Li H, de Faria JP, Emery B,
Tohyama K, et al. (2014). Motor skill learning requires
active central myelination. Science, 346: 318-322
Kawasaki T, Kawai T (2014). Toll-like receptor
signaling pathways. Front Immunol, 5: 461
Herber DL, Roth LM, Wilson D, Wilson N, Mason JE,
Morgan D, et al. (2004). Time-dependent reduction in
Abeta levels after intracranial LPS administration in
APP transgenic mice. Exp Neurol, 190: 245-253
Herber DL, Mercer M, Roth LM, Symmonds K,
Maloney J, Wilson N, et al. (2007). Microglial
activation is required for Abeta clearance after
intracranial injection of lipopolysaccharide in APP
transgenic mice. J Neuroimmune Pharmacol, 2: 222231
Laskin DL, Pendino KJ (1995). Macrophages and
inflammatory mediators in tissue injury. Annu Rev
Pharmacol Toxicol, 35: 655-677
Wyss-Coray T (2006). Inflammation in Alzheimer
disease: driving force, bystander or beneficial
response? Nat Med, 12: 1005-1015
Akiyama H, Arai T, Kondo H, Tanno E, Haga C, Ikeda
K (2000). Cell mediators of inflammation in the
Alzheimer disease brain. Alzheimer Dis Assoc Disord,
14 Suppl 1: S47-53
Li Y, Liu L, Barger SW, Griffin WS (2003).
Interleukin-1 mediates pathological effects of
microglia on tau phosphorylation and on
synaptophysin synthesis in cortical neurons through a
p38-MAPK pathway. J Neurosci, 23: 1605-1611
Quintanilla RA, Orellana DI, Gonzalez-Billault C,
Maccioni RB (2004). Interleukin-6 induces
Alzheimer-type phosphorylation of tau protein by
deregulating the cdk5/p35 pathway. Exp Cell Res, 295:
245-257
Benzi G, Moretti A (1995). Are reactive oxygen
species involved in Alzheimer's disease? Neurobiol
Aging, 16: 661-674
Weldon DT, Rogers SD, Ghilardi JR, Finke MP,
Cleary JP, O'Hare E, et al. (1998). Fibrillar betaamyloid induces microglial phagocytosis, expression
of inducible nitric oxide synthase, and loss of a select
population of neurons in the rat CNS in vivo. J
Neurosci, 18: 2161-2173
Olivieri F, Rippo MR, Procopio AD, Fazioli F (2013).
Circulating inflamma-miRs in aging and age-related
diseases. Front Genet, 4: 121
Galea I, Bechmann I, Perry VH (2007). What is
immune privilege (not)? Trends Immunol, 28: 12-18
Alvarez JI, Katayama T, Prat A (2013). Glial influence
on the blood brain barrier. Glia, 61: 1939-1958

347

Sarkar SN., et al
[95]
[96]

[97]

[98]

[99]

[100]

[101]

[102]

[103]

[104]

[105]
[106]

[107]

[108]

Prat A, Biernacki K, Wosik K, Antel JP (2001). Glial
cell influence on the human blood-brain barrier. Glia,
36: 145-155
Benros ME, Sorensen HJ, Nielsen PR, Nordentoft M,
Mortensen PB, Petersen L (2015). The association
between infections and general cognitive ability in
young men - A nationwide study. PLoS One, 10:
e0124005
Gow AJ, Firth CM, Harrison R, Starr JM, Moss P,
Deary IJ (2013). Cytomegalovirus infection and
cognitive abilities in old age. Neurobiol Aging, 34:
1846-1852
Riva S, Cutica I, Krampe C, Reinecke LF, Russell-Edu
W, Santoro C, et al. (2015). A cohort pilot study on
HIV-associated neuropsychological impairments in
Hemophilia patients. Front Hum Neurosci, 9: 313
Abraham J, Johnson RW (2009). Consuming a diet
supplemented with resveratrol reduced infectionrelated neuroinflammation and deficits in working
memory in aged mice. Rejuvenation Res, 12: 445-453
Chen J, Buchanan JB, Sparkman NL, Godbout JP,
Freund GG, Johnson RW (2008). Neuroinflammation
and disruption in working memory in aged mice after
acute stimulation of the peripheral innate immune
system. Brain Behav Immun, 22: 301-311
Lee JW, Lee YK, Yuk DY, Choi DY, Ban SB, Oh KW,
et al. (2008). Neuro-inflammation induced by
lipopolysaccharide causes cognitive impairment
through enhancement of beta-amyloid generation. J
Neuroinflammation, 5: 37
Sheng JG, Bora SH, Xu G, Borchelt DR, Price DL,
Koliatsos VE (2003). Lipopolysaccharide-inducedneuroinflammation
increases
intracellular
accumulation of amyloid precursor protein and
amyloid beta peptide in APPswe transgenic mice.
Neurobiol Dis, 14: 133-145
Sy M, Kitazawa M, Medeiros R, Whitman L, Cheng
D, Lane TE, et al. (2011). Inflammation induced by
infection potentiates tau pathological features in
transgenic mice. Am J Pathol, 178: 2811-2822
Weintraub MK, Kranjac D, Eimerbrink MJ, Pearson
SJ, Vinson BT, Patel J, et al. (2014). Peripheral
administration of poly I:C leads to increased
hippocampal amyloid-beta and cognitive deficits in a
non-transgenic mouse. Behav Brain Res, 266: 183-187
Veerhuis R (2011). Histological and direct evidence
for the role of complement in the neuroinflammation
of AD. Curr Alzheimer Res, 8: 34-58
Nottet HS, Persidsky Y, Sasseville VG, Nukuna AN,
Bock P, Zhai QH, et al. (1996). Mechanisms for the
transendothelial migration of HIV-1-infected
monocytes into brain. J Immunol, 156: 1284-1295
Persidsky Y, Gendelman HE (1997). Development of
laboratory and animal model systems for HIV-1
encephalitis and its associated dementia. J Leukoc
Biol, 62: 100-106
Bell MD, Taub DD, Perry VH (1996). Overriding the
brain's intrinsic resistance to leukocyte recruitment
with intraparenchymal injections of recombinant
chemokines. Neuroscience, 74: 283-292

Aging and Disease • Volume 10, Number 2, April 2019

microRNAs in Aging and Disease
[109]
[110]
[111]

[112]

[113]

[114]
[115]

[116]

[117]

[118]
[119]

[120]

[121]
[122]

[123]

[124]

Hickey WF, Hsu, B.L., Kimura, H. (1991). Tlymphocyte entry into the central nervous system.
Journal of Neuroscience Research, 28: 254-260
Wekerle H, Linington C, Lassmann H, Meyermann R
Cellular immune reactivity within the CNS. Trends in
Neurosciences, 9: 271-277
Montagne A, Barnes SR, Sweeney MD, Halliday MR,
Sagare AP, Zhao Z, et al. (2015). Blood-brain barrier
breakdown in the aging human hippocampus. Neuron,
85: 296-302
Lopez-Ramirez MA, Wu D, Pryce G, Simpson JE,
Reijerkerk A, King-Robson J, et al. (2014).
MicroRNA-155 negatively affects blood-brain barrier
function during neuroinflammation. FASEB J, 28:
2551-2565
Liu W, Cai H, Lin M, Zhu L, Gao L, Zhong R, et al.
(2016). MicroRNA-107 prevents amyloid-beta
induced blood-brain barrier disruption and endothelial
cell dysfunction by targeting Endophilin-1. Exp Cell
Res, 343: 248-257
Abbott NJ (2002). Astrocyte-endothelial interactions
and blood-brain barrier permeability. J Anat, 200: 629638
Bukeirat M, Sarkar SN, Hu H, Quintana DD, Simpkins
JW, Ren X (2016). MiR-34a regulates blood-brain
barrier permeability and mitochondrial function by
targeting cytochrome c. J Cereb Blood Flow Metab, 36:
387-392
Rom S, Dykstra H, Zuluaga-Ramirez V, Reichenbach
NL, Persidsky Y (2015). miR-98 and let-7g* protect
the blood-brain barrier under neuroinflammatory
conditions. J Cereb Blood Flow Metab, 35: 1957-1965
Zeevi N, Pachter J, McCullough LD, Wolfson L,
Kuchel GA (2010). The blood-brain barrier: geriatric
relevance of a critical brain-body interface. J Am
Geriatr Soc, 58: 1749-1757
Shah GN, Mooradian AD (1997). Age-related changes
in the blood-brain barrier. Exp Gerontol, 32: 501-519
Dermietzel R, Leibstein AG (1978). The
microvascular pattern and perivascular linings of the
area postrema. A combined freeze-etching and
ultrathin section study. Cell Tissue Res, 186: 97-110
Davalos D, Grutzendler J, Yang G, Kim JV, Zuo Y,
Jung S, et al. (2005). ATP mediates rapid microglial
response to local brain injury in vivo. Nat Neurosci, 8:
752-758
Gehrmann J, Matsumoto Y, Kreutzberg GW (1995).
Microglia: intrinsic immuneffector cell of the brain.
Brain Res Brain Res Rev, 20: 269-287
Morris GP, Clark IA, Zinn R, Vissel B (2013).
Microglia: a new frontier for synaptic plasticity,
learning and memory, and neurodegenerative disease
research. Neurobiol Learn Mem, 105: 40-53
Nimmerjahn A, Kirchhoff F, Helmchen F (2005).
Resting microglial cells are highly dynamic
surveillants of brain parenchyma in vivo. Science, 308:
1314-1318
Schafer DP, Lehrman EK, Kautzman AG, Koyama R,
Mardinly AR, Yamasaki R, et al. (2012). Microglia
sculpt postnatal neural circuits in an activity and

348

Sarkar SN., et al

[125]

[126]

[127]
[128]

[129]
[130]
[131]
[132]

[133]

[134]
[135]

[136]

[137]

[138]

[139]

complement-dependent manner. Neuron, 74: 691-705
Gonzalez H, Elgueta D, Montoya A, Pacheco R (2014).
Neuroimmune regulation of microglial activity
involved in neuroinflammation and neurodegenerative
diseases. J Neuroimmunol, 274: 1-13
Wu LJ, Vadakkan KI, Zhuo M (2007). ATP-induced
chemotaxis of microglial processes requires P2Y
receptor-activated initiation of outward potassium
currents. Glia, 55: 810-821
Perry RT, Collins JS, Wiener H, Acton R, Go RC
(2001). The role of TNF and its receptors in
Alzheimer's disease. Neurobiol Aging, 22: 873-883
Rock RB, Gekker G, Hu S, Sheng WS, Cheeran M,
Lokensgard JR, et al. (2004). Role of microglia in
central nervous system infections. Clin Microbiol Rev,
17: 942-964, table of contents
Tuppo EE, Arias HR (2005). The role of inflammation
in Alzheimer's disease. Int J Biochem Cell Biol, 37:
289-305
Selkoe DJ (1994). Normal and abnormal biology of
the Beta-Amyloid precursor protein. Annu Rev
Neurosci, 17: 489-517
Nicolas M, Hassan BA (2014). Amyloid precursor
protein and neural development. Development, 141:
2543-2548
Falcão AS, Carvalho LAR, Lidónio G, Vaz AR, Lucas
SD, Moreira R, et al. (2017). Dipeptidyl vinyl sulfone
as a novel chemical tool to inhibit HMGB1/NLRP3inflammasome and inflamma-miRs in Aβ-mediated
microglial
inflammation.
ACS
Chemical
Neuroscience, 8: 89-99
Eikelenboom P, Veerhuis R, Scheper W, Rozemuller
AJ, van Gool WA, Hoozemans JJ (2006). The
significance of neuroinflammation in understanding
Alzheimer's disease. J Neural Transm (Vienna), 113:
1685-1695
Hong S, Dissing-Olesen L, Stevens B (2016). New
insights on the role of microglia in synaptic pruning in
health and disease. Curr Opin Neurobiol, 36: 128-134
Uslu S, Akarkarasu ZE, Ozbabalik D, Ozkan S, Colak
O, Demirkan ES, et al. (2012). Levels of amyloid beta42, interleukin-6 and tumor necrosis factor-alpha in
Alzheimer's disease and vascular dementia.
Neurochem Res, 37: 1554-1559
Eikelenboom P, Hack CE, Rozemuller JM, Stam FC
(1989). Complement activation in amyloid plaques in
Alzheimer's dementia. Virchows Arch B Cell Pathol
Incl Mol Pathol, 56: 259-262
Lian H, Litvinchuk A, Chiang AC, Aithmitti N,
Jankowsky JL, Zheng H (2016). Astrocyte-microglia
cross talk through complement activation modulates
amyloid pathology in mouse models of Alzheimer's
disease. J Neurosci, 36: 577-589
Fu H, Liu B, Frost JL, Hong S, Jin M, Ostaszewski B,
et al. (2012). Complement component C3 and
complement receptor type 3 contribute to the
phagocytosis and clearance of fibrillar Abeta by
microglia. Glia, 60: 993-1003
Rogers J, Cooper NR, Webster S, Schultz J, McGeer
PL, Styren SD, et al. (1992). Complement activation

Aging and Disease • Volume 10, Number 2, April 2019

microRNAs in Aging and Disease

[140]

[141]
[142]

[143]

[144]
[145]
[146]

[147]

[148]

[149]

[150]
[151]
[152]

[153]

[154]

by beta-amyloid in Alzheimer disease. Proc Natl Acad
Sci U S A, 89: 10016-10020
Akiyama H, Schwab C, Kondo H, Mori H, Kametani
F, Ikeda K, et al. (1996). Granules in glial cells of
patients with Alzheimer's disease are immunopositive
for C-terminal sequences of beta-amyloid protein.
Neurosci Lett, 206: 169-172
Kopec KK, Carroll RT (1998). Alzheimer's betaamyloid peptide 1-42 induces a phagocytic response in
murine microglia. J Neurochem, 71: 2123-2131
Ard MD, Cole GM, Wei J, Mehrle AP, Fratkin JD
(1996). Scavenging of Alzheimer's amyloid betaprotein by microglia in culture. J Neurosci Res, 43:
190-202
Frackowiak J, Wisniewski HM, Wegiel J, Merz GS,
Iqbal K, Wang KC (1992). Ultrastructure of the
microglia that phagocytose amyloid and the microglia
that produce beta-amyloid fibrils. Acta Neuropathol,
84: 225-233
Guedes J, Cardoso AL, Pedroso de Lima MC (2013).
Involvement of microRNA in microglia-mediated
immune response. Clin Dev Immunol, 2013: 186872
Cho KJ, Song J, Oh Y, Lee JE (2015). MicroRNA-Let7a regulates the function of microglia in inflammation.
Mol Cell Neurosci, 68: 167-176
Ponomarev ED, Veremeyko T, Barteneva N,
Krichevsky AM, Weiner HL (2011). MicroRNA-124
promotes microglia quiescence and suppresses EAE
by deactivating macrophages via the C/EBP-alphaPU.1 pathway. Nat Med, 17: 64-70
Cardoso AL, Guedes JR, Pereira de Almeida L,
Pedroso de Lima MC (2012). miR-155 modulates
microglia-mediated immune response by downregulating SOCS-1 and promoting cytokine and nitric
oxide production. Immunology, 135: 73-88
Wang P, Hou J, Lin L, Wang C, Liu X, Li D, et al.
(2010). Inducible microRNA-155 feedback promotes
type I IFN signaling in antiviral innate immunity by
targeting suppressor of cytokine signaling 1. J
Immunol, 185: 6226-6233
Dalpke A, Heeg K, Bartz H, Baetz A (2008).
Regulation of innate immunity by suppressor of
cytokine signaling (SOCS) proteins. Immunobiology,
213: 225-235
Koellhoffer EC, McCullough LD, Ritzel RM (2017).
Old Maids: Aging and its impact on microglia function.
Int J Mol Sci, 18
Mosher KI, Wyss-Coray T (2014). Microglial
Dysfunction in Brain Aging and Alzheimer’s Disease.
Biochemical pharmacology, 88: 594-604
Crain JM, Nikodemova M, Watters JJ (2013).
Microglia express distinct M1 and M2 phenotypic
markers in the postnatal and adult central nervous
system in male and female mice. Journal of
Neuroscience Research, 91: 1143-1151
Spittau B (2017). Aging microglia-phenotypes,
functions and implications for age-related
neurodegenerative diseases. Front Aging Neurosci, 9:
194
Cherry JD, Olschowka JA, O'Banion MK (2014).

349

Sarkar SN., et al

[155]

[156]
[157]
[158]

[159]

[160]

[161]

[162]

[163]

[164]

[165]

[166]
[167]
[168]
[169]

Neuroinflammation and M2 microglia: the good, the
bad, and the inflamed. J Neuroinflammation, 11: 98
Zhou T, Huang Z, Sun X, Zhu X, Zhou L, Li M, et al.
(2017). Microglia polarization with M1/M2 phenotype
changes in rd1 mouse model of retinal degeneration.
Front Neuroanat, 11: 77
Ransohoff RM (2016). A polarizing question: do M1
and M2 microglia exist? Nature Neuroscience, 19:
987-991
Mittelbronn M (2014). The M1/M2 immune
polarization concept in microglia: a fair transfer?
Neuroimmunology and Neuroinflammation, 1: 6-7
Zhu QY, Liu Q, Chen JX, Lan K, Ge BX (2010).
MicroRNA-101 targets MAPK phosphatase-1 to
regulate the activation of MAPKs in macrophages. J
Immunol, 185: 7435-7442
Chaudhuri AA, So AY, Sinha N, Gibson WS, Taganov
KD, O'Connell RM, et al. (2011). MicroRNA-125b
potentiates macrophage activation. J Immunol, 187:
5062-5068
Lai L, Song Y, Liu Y, Chen Q, Han Q, Chen W, et al.
(2013). MicroRNA-92a negatively regulates Toll-like
receptor (TLR)-triggered inflammatory response in
macrophages by targeting MKK4 kinase. J Biol Chem,
288: 7956-7967
Franceschi C, Campisi J (2014). Chronic
inflammation (inflammaging) and its potential
contribution to age-associated diseases. J Gerontol A
Biol Sci Med Sci, 69 Suppl 1: S4-9
Byun HO, Lee YK, Kim JM, Yoon G (2016). Erratum
to: From cell senescence to age-related diseases:
differential mechanisms of action of senescenceassociated secretory phenotypes. BMB Rep, 49: 641650
Vasa-Nicotera M, Chen H, Tucci P, Yang AL,
Saintigny G, Menghini R, et al. (2011). miR-146a is
modulated in human endothelial cell with aging.
Atherosclerosis, 217: 326-330
Zhao T, Li J, Chen AF (2010). MicroRNA-34a induces
endothelial progenitor cell senescence and impedes its
angiogenesis via suppressing silent information
regulator 1. Am J Physiol Endocrinol Metab, 299:
E110-116
Magill ST, Cambronne XA, Luikart BW, Lioy DT,
Leighton BH, Westbrook GL, et al. (2010).
microRNA-132 regulates dendritic growth and
arborization of newborn neurons in the adult
hippocampus. Proc Natl Acad Sci U S A, 107: 2038220387
Nampoothiri SS, Rajanikant GK (2017). Decoding the
ubiquitous role of microRNAs in neurogenesis. Mol
Neurobiol, 54: 2003-2011
Hu Z, Li Z (2017). miRNAs in synapse development
and synaptic plasticity. Curr Opin Neurobiol, 45: 2431
Steward O, Schuman EM (2001). Protein synthesis at
synaptic sites on dendrites. Annu Rev Neurosci, 24:
299-325
Kosik KS (2006). The neuronal microRNA system.
Nat Rev Neurosci, 7: 911-920

Aging and Disease • Volume 10, Number 2, April 2019

microRNAs in Aging and Disease
[170]

[171]
[172]

[173]

[174]

[175]

[176]

[177]

[178]

[179]

[180]
[181]
[182]
[183]

[184]

[185]

Schratt GM, Tuebing F, Nigh EA, Kane CG, Sabatini
ME, Kiebler M, et al. (2006). A brain-specific
microRNA regulates dendritic spine development.
Nature, 439: 283
Association As (2017) Alzheimer's disease facts and
figures.
Chen X, Jiang XM, Zhao LJ, Sun LL, Yan ML, Tian Y,
et al. (2017). MicroRNA-195 prevents dendritic
degeneration and neuron death in rats following
chronic brain hypoperfusion. Cell Death Dis, 8: e2850
Fan C, Wu Q, Ye X, Luo H, Yan D, Xiong Y, et al.
(2016). Role of miR-211 in Neuronal Differentiation
and Viability: Implications to Pathogenesis of
Alzheimer's Disease. Front Aging Neurosci, 8: 166
Teri L, Ferretti LE, Gibbons LE, Logsdon RG,
McCurry SM, Kukull WA, et al. (1999). Anxiety of
Alzheimer's disease: prevalence, and comorbidity. J
Gerontol A Biol Sci Med Sci, 54: M348-352
Blazquez G, Canete T, Tobena A, Gimenez-Llort L,
Fernandez-Teruel A (2014). Cognitive and emotional
profiles of aged Alzheimer's disease (3xTgAD) mice:
effects of environmental enrichment and sexual
dimorphism. Behav Brain Res, 268: 185-201
Pristera A, Saraulli D, Farioli-Vecchioli S, Strimpakos
G, Costanzi M, di Certo MG, et al. (2013). Impact of
N-tau on adult hippocampal neurogenesis, anxiety,
and memory. Neurobiol Aging, 34: 2551-2563
Li X, Wang Z, Tan L, Wang Y, Lu C, Chen R, et al.
(2017).
Correcting
miR92a-vGAT-mediated
GABAergic dysfunctions rescues human Tau-induced
anxiety in mice. Mol Ther, 25: 140-152
Wang Y, Veremeyko T, Wong AH, El Fatimy R, Wei Z,
Cai W, et al. (2017). Downregulation of miR-132/212
impairs S-nitrosylation balance and induces tau
phosphorylation in Alzheimer's disease. Neurobiol
Aging, 51: 156-166
Xu B, Zhang Y, Du XF, Li J, Zi HX, Bu JW, et al.
(2017). Neurons secrete miR-132-containing
exosomes to regulate brain vascular integrity. Cell Res,
27: 882-897
Kumar S, Reddy PH (2016). Are circulating
microRNAs peripheral biomarkers for Alzheimer's
disease? Biochim Biophys Acta, 1862: 1617-1627
Basavaraju M, de Lencastre A (2016). Alzheimer's
disease: presence and role of microRNAs. Biomol
Concepts, 7: 241-252
Geekiyanage H, Jicha GA, Nelson PT, Chan C (2012).
Blood serum miRNA: non-invasive biomarkers for
Alzheimer's disease. Exp Neurol, 235: 491-496
Tan L, Yu J-T, Liu Q-Y, Tan M-S, Zhang W, Hu N, et
al. (2014). Circulating miR-125b as a biomarker of
Alzheimer's disease. Journal of the Neurological
Sciences, 336: 52-56
Fengler S, Liepelt-Scarfone I, Brockmann K, Schaffer
E, Berg D, Kalbe E (2017). Cognitive changes in
prodromal Parkinson's disease: A review. Mov Disord,
32: 1655-1666
Bai X, Tang Y, Yu M, Wu L, Liu F, Ni J, et al. (2017).
Downregulation of blood serum microRNA 29 family
in patients with Parkinson's disease. Sci Rep, 7: 5411

350

Sarkar SN., et al
[186]

[187]

[188]

[189]

[190]

[191]

[192]

[193]

[194]

[195]

[196]

[197]

[198]

Margis R, Margis R, Rieder CRM (2011).
Identification of blood microRNAs associated to
Parkinsońs disease. Journal of Biotechnology, 152:
96-101
Zhang X, Yang R, Hu BL, Lu P, Zhou LL, He ZY, et
al. (2017). Reduced circulating levels of miR-433 and
miR-133b are potential biomarkers for Parkinson's
disease. Front Cell Neurosci, 11: 170
Kim J, Inoue K, Ishii J, Vanti WB, Voronov SV,
Murchison E, et al. (2007). A MicroRNA feedback
circuit in midbrain dopamine neurons. Science, 317:
1220-1224
Yang CP, Zhang ZH, Zhang LH, Rui HC (2016).
Neuroprotective role of microRNA-22 in a 6hydroxydopamine-induced cell model of Parkinson's
disease via regulation of its target gene TRPM7. J Mol
Neurosci, 60: 445-452
Zhao N, Jin L, Fei G, Zheng Z, Zhong C (2014). Serum
microRNA-133b is associated with low ceruloplasmin
levels in Parkinson's disease. Parkinsonism Relat
Disord, 20: 1177-1180
Schlaudraff F, Grundemann J, Fauler M, Dragicevic E,
Hardy J, Liss B (2014). Orchestrated increase of
dopamine and PARK mRNAs but not miR-133b in
dopamine neurons in Parkinson's disease. Neurobiol
Aging, 35: 2302-2315
Heyer MP, Pani AK, Smeyne RJ, Kenny PJ, Feng G
(2012). Normal midbrain dopaminergic neuron
development and function in miR-133b mutant mice.
J Neurosci, 32: 10887-10894
de Mena L, Cardo LF, Coto E, Miar A, Díaz M, Corao
AI, et al. (2010). FGF20 rs12720208 SNP and
microRNA-433 variation: No association with
Parkinson's disease in Spanish patients. Neuroscience
Letters, 479: 22-25
Chen Y, Gao C, Sun Q, Pan H, Huang P, Ding J, et al.
(2017). MicroRNA-4639 is a regulator of DJ-1
expression and a potential early diagnostic marker for
Parkinson’s disease. Frontiers in Aging Neuroscience,
9
Kanagaraj N, Beiping H, Dheen ST, Tay SS (2014).
Downregulation of miR-124 in MPTP-treated mouse
model of Parkinson's disease and MPP iodide-treated
MN9D cells modulates the expression of the
calpain/cdk5 pathway proteins. Neuroscience, 272:
167-179
Wei M, Cao LJ, Zheng JL, Xue LJ, Chen B, Xiao F, et
al. (2017). MicroRNA-181c functions as a protective
factor in a 1-methyl-4-phenylpyridinium iodideinduced cellular Parkinson's disease model via
BCL2L11. Eur Rev Med Pharmacol Sci, 21: 32963304
Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das
SR, Deo R, et al. (2017). Heart disease and stroke
statistics-2017 update: A report from the American
Heart Association. Circulation, 135: e146-e603
Zhang L, Dong LY, Li YJ, Hong Z, Wei WS (2012).
The microRNA miR-181c controls microgliamediated neuronal apoptosis by suppressing tumor
necrosis factor. J Neuroinflammation, 9: 211

Aging and Disease • Volume 10, Number 2, April 2019

microRNAs in Aging and Disease
[199]

[200]

[201]

[202]

[203]

[204]

[205]

[206]

[207]

[208]

[209]

[210]

[211]

[212]

Ouyang YB, Lu Y, Yue S, Xu LJ, Xiong XX, White
RE, et al. (2012). miR-181 regulates GRP78 and
influences outcome from cerebral ischemia in vitro
and in vivo. Neurobiol Dis, 45: 555-563
Moon JM, Xu L, Giffard RG (2013). Inhibition of
microRNA-181 reduces forebrain ischemia-induced
neuronal loss. J Cereb Blood Flow Metab, 33: 19761982
Fan Y, Ding S, Sun Y, Zhao B, Pan Y, Wan J (2018).
MiR-377 regulates inflammation and angiogenesis in
rats after cerebral ischemic injury. J Cell Biochem, 119:
327-337
Liu DZ, Jickling GC, Ander BP, Hull H, Zhan X, Cox
C, et al. (2016). Elevating microRNA-122 in blood
improves outcomes after temporary middle cerebral
artery occlusion in rats. J Cereb Blood Flow Metab, 36:
1374-1383
Stanzione R, Bianchi F, Cotugno M, Marchitti S, Forte
M, Busceti C, et al. (2017). A decrease of brain
microRNA-122 level is an early marker of
cerebrovascular disease in the stroke-prone
spontaneously hypertensive rat. Oxid Med Cell
Longev, 2017: 1206420
Cerutti C, Edwards LJ, de Vries HE, Sharrack B, Male
DK, Romero IA (2017). MiR-126 and miR-126*
regulate shear-resistant firm leukocyte adhesion to
human brain endothelium. Sci Rep, 7: 45284
Chen J, Cui C, Yang X, Xu J, Venkat P, Zacharek A, et
al. (2017). MiR-126 affects brain-heart interaction
after cerebral ischemic stroke. Transl Stroke Res, 8:
374-385
Su ZF, Sun ZW, Zhang Y, Wang S, Yu QG, Wu ZB
(2017). Regulatory effects of miR-146a/b on the
function of endothelial progenitor cells in acute
ischemic stroke in mice. Kaohsiung J Med Sci, 33:
369-378
Madelaine R, Sloan SA, Huber N, Notwell JH, Leung
LC, Skariah G, et al. (2017). MicroRNA-9 couples
brain neurogenesis and angiogenesis. Cell Rep, 20:
1533-1542
Zheng Y, Wang L, Chen M, Pei A, Xie L, Zhu S (2017).
Upregulation of miR-130b protects against cerebral
ischemic injury by targeting water channel protein
aquaporin 4 (AQP4). Am J Transl Res, 9: 3452-3461
Yu LS, Fan YY, Ye G, Li J, Feng XP, Lin K, et al.
(2016). Curcumin alleviates brain edema by lowering
AQP4 expression levels in a rat model of hypoxiahypercapnia-induced brain damage. Exp Ther Med, 11:
709-716
Shi G, Liu Y, Liu T, Yan W, Liu X, Wang Y, et al.
(2012). Upregulated miR-29b promotes neuronal cell
death by inhibiting Bcl2L2 after ischemic brain injury.
Exp Brain Res, 216: 225-230
Huang LG, Li JP, Pang XM, Chen CY, Xiang HY, Feng
LB, et al. (2015). MicroRNA-29c correlates with
neuroprotection induced by FNS by targeting both
Birc2 and Bak1 in rat brain after stroke. CNS Neurosci
Ther, 21: 496-503
Wang Y, Huang J, Ma Y, Tang G, Liu Y, Chen X, et al.
(2015). MicroRNA-29b is a therapeutic target in

351

Sarkar SN., et al

[213]

[214]

[215]

[216]

[217]

[218]

[219]

[220]

[221]

[222]

[223]

[224]

[225]

cerebral ischemia associated with aquaporin 4. J Cereb
Blood Flow Metab, 35: 1977-1984
Khanna S, Rink C, Ghoorkhanian R, Gnyawali S,
Heigel M, Wijesinghe DS, et al. (2013). Loss of miR29b following acute ischemic stroke contributes to
neural cell death and infarct size. J Cereb Blood Flow
Metab, 33: 1197-1206
Yang L, Xiong Y, Hu XF, Du YH (2015). MicroRNA323 regulates ischemia/reperfusion injury-induced
neuronal cell death by targeting BRI3. Int J Clin Exp
Pathol, 8: 10725-10733
Wang P, Liang J, Li Y, Li J, Yang X, Zhang X, et al.
(2014) Down-Regulation of miRNA-30a alleviates
cerebral ischemic injury through enhancing beclin 1mediated autophagy. Neurochem Res, 39: 1279-1291
Zhu F, Liu J-L, Li J-P, Xiao F, Zhang Z-X, Zhang L
(2014). MicroRNA-124 (miR-124) regulates Ku70
expression and is correlated with neuronal death
induced by ischemia/reperfusion. Journal of
Molecular Neuroscience, 52: 148-155
Liu XS, Chopp M, Zhang RL, Tao T, Wang XL, Kassis
H, et al. (2011). MicroRNA profiling in subventricular
zone after stroke: MiR-124a regulates proliferation of
neural progenitor cells through Notch signaling
pathway. PLoS One, 6: e23461
Liu X, Li F, Zhao S, Luo Y, Kang J, Zhao H, et al.
(2013). MicroRNA-124-mediated regulation of
inhibitory member of apoptosis-stimulating protein of
p53 family in experimental stroke. Stroke, 44: 19731980
Doeppner TR, Doehring M, Bretschneider E,
Zechariah A, Kaltwasser B, Muller B, et al. (2013).
MicroRNA-124 protects against focal cerebral
ischemia via mechanisms involving Usp14-dependent
REST degradation. Acta Neuropathol, 126: 251-265
Sun Y, Gui H, Li Q, Luo ZM, Zheng MJ, Duan JL, et
al. (2013). MicroRNA-124 protects neurons against
apoptosis in cerebral ischemic stroke. CNS Neurosci
Ther, 19: 813-819
Siegel C, Li J, Liu F, Benashski SE, McCullough LD
(2011). miR-23a regulation of X-linked inhibitor of
apoptosis (XIAP) contributes to sex differences in the
response to cerebral ischemia. Proc Natl Acad Sci U S
A, 108: 11662-11667
Selvamani A, Sathyan P, Miranda RC, Sohrabji F
(2012). An antagomir to microRNA Let7f promotes
neuroprotection in an ischemic stroke model. PLoS
One, 7: e32662
Tiedt S, Prestel M, Malik R, Schieferdecker N,
Duering M, Kautzky V, et al. (2017). RNA-Seq
identifies circulating miR-125a-5p, miR-125b-5p, and
miR-143-3p as potential biomarkers for acute
ischemic stroke. Circ Res, 121: 970-980
Sorensen SS, Nygaard AB, Nielsen MY, Jensen K,
Christensen T (2014). miRNA expression profiles in
cerebrospinal fluid and blood of patients with acute
ischemic stroke. Transl Stroke Res, 5: 711-718
Jeyaseelan K, Lim KY, Armugam A (2008).
MicroRNA expression in the blood and brain of rats
subjected to transient focal ischemia by middle

Aging and Disease • Volume 10, Number 2, April 2019

microRNAs in Aging and Disease

[226]

[227]

[228]

[229]
[230]
[231]

[232]

[233]

[234]

cerebral artery occlusion. Stroke, 39: 959-966
Liu DZ, Tian Y, Ander BP, Xu H, Stamova BS, Zhan
X, et al. (2010). Brain and blood microRNA
expression profiling of ischemic stroke, intracerebral
hemorrhage, and kainate seizures. J Cereb Blood Flow
Metab, 30: 92-101
Gurman P, Miranda OR, Nathan A, Washington C,
Rosen Y, Elman NM (2015). Recombinant tissue
plasminogen activators (rtPA): a review. Clin
Pharmacol Ther, 97: 274-285
Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman
SK, Pogosova-Agadjanyan EL, et al. (2008).
Circulating microRNAs as stable blood-based markers
for cancer detection. Proceedings of the National
Academy of Sciences, 105: 10513-10518
Turchinovich A, Weiz L, Burwinkel B (2012).
Extracellular miRNAs: the mystery of their origin and
function. Trends Biochem Sci, 37: 460-465
Boon RA, Vickers KC (2013). Intercellular transport
of microRNAs. Arterioscler Thromb Vasc Biol, 33:
186-192
Barbash S, Simchovitz A, Buchman AS, Bennett DA,
Shifman S, Soreq H (2017). Neuronal-expressed
microRNA-targeted pseudogenes compete with
coding genes in the human brain. Translational
Psychiatry, 7: e1199
Cai Y, Sun Z, Jia H, Luo H, Ye X, Wu Q, et al. (2017).
Rpph1 upregulates CDC42 expression and promotes
hippocampal neuron dendritic spine formation by
competing with miR-330-5p. Front Mol Neurosci, 10:
27
Saraiva C, Esteves M, Bernardino L (2017).
MicroRNA: Basic concepts and implications for
regeneration and repair of neurodegenerative diseases.
Biochem Pharmacol, 141: 118-131
Bernardo BC, Ooi JY, Lin RC, McMullen JR (2015).
miRNA therapeutics: a new class of drugs with
potential therapeutic applications in the heart. Future
Med Chem, 7: 1771-1792

352

